WO2009125597A1 - アシルチオウレア化合物又はその塩、及びその用途 - Google Patents
アシルチオウレア化合物又はその塩、及びその用途 Download PDFInfo
- Publication number
- WO2009125597A1 WO2009125597A1 PCT/JP2009/001655 JP2009001655W WO2009125597A1 WO 2009125597 A1 WO2009125597 A1 WO 2009125597A1 JP 2009001655 W JP2009001655 W JP 2009001655W WO 2009125597 A1 WO2009125597 A1 WO 2009125597A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- substituent
- carboxamide
- thioureido
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a novel acylthiourea compound or a salt thereof, and a use thereof.
- C-Met is a receptor tyrosine kinase identified as one of the proto-oncogenes, and exerts physiological functions by binding to ligand HGF. In normal tissues, it contributes to regeneration, wound healing and organ formation, but many cancers (renal cell cancer, stomach cancer, lung cancer, colon cancer, pancreatic cancer, ovarian cancer, hepatocellular carcinoma, head and neck cancer, melanoma, etc.
- Non-patent Document 1 C-Met is over-expressed, mutated or translocated at a high frequency, resulting in an increased activation state (Non-patent Document 1), cell proliferation, invasion / metastasis, tumor formation, angiogenesis, It has been reported that it contributes to anti-apoptosis (Non-patent Documents 2, 3, and 4).
- Non-patent Documents 2, 3, and 4 overexpression of c-Met and increased activation level in these cancers have been reported to be inversely correlated with prognosis, and c-Met is also known as a poor prognosis factor for cancer ( Non-Patent Documents 5 and 6).
- acylthiourea compounds have been widely studied as compounds useful for medicines and the like (for example, Patent Documents 1 to 7).
- Patent Documents 1 to 7 there is no report on the acylthiourea compound of the present invention represented by the general formula (I) having an aminocarbonyl group as the 6-position substituent of the quinoline ring and an alkoxy group as the 7-position substituent.
- the present invention provides an antitumor agent having an excellent c-Met inhibitory action and having high selectivity for tumor cells in which c-Met is specifically expressed, thereby reducing side effects. Objective.
- the acylthiourea compound represented by the following general formula (I) having an aminocarbonyl group at the 6-position of the quinoline ring and an alkoxy group at the 7-position is an existing compound having an inhibitory action on c-Met.
- c-Met inhibitory effect equivalent to or higher than that of existing compounds and (2) tumor cells and low levels of c-Met.
- c-Met is highly selective for tumor cells overexpressed and highly activated, and (3) side effects are reduced and strong tumors are observed in in vivo tests using nude mice. It was found to show a regression effect.
- the acylthiourea compound represented by the general formula (I) selectively acts on tumor cells in which c-Met is specifically expressed, it has few side effects and is useful as an excellent antitumor agent. I found out. The present invention has been completed based on such findings.
- R 1 and R 2 are the same or different and are a hydrogen atom, a C 1-6 alkyl group which may have a substituent, or a C 3-10 cycloalkyl which may have a substituent
- a nitrogen-containing heterocyclic ring which may have a substituent together with the nitrogen atom may be formed
- R 3 represents a C 1-6 alkyl group
- R 4 , R 5 and R 6 are the same or different and each represents a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkylamino A group, an aromatic hydrocarbon group which may have a substituent, or a saturated or unsaturated heterocyclic group which may have a substituent, or R 5 and R 6 together with the phen
- the acylthiourea compound represented by these, or its salt is provided.
- the present invention also provides a pharmaceutical comprising the acylthiourea compound represented by the above general formula (I) or a salt thereof as an active ingredient.
- the present invention also provides a pharmaceutical composition comprising the acylthiourea compound represented by the above general formula (I) or a salt thereof, and a pharmaceutically acceptable carrier.
- the present invention also provides use of the acylthiourea compound represented by the above general formula (I) or a salt thereof for the production of an antitumor agent.
- the present invention provides a method for treating cancer, comprising administering an effective amount of the compound acylthiourea compound represented by the above general formula (I) or a salt thereof.
- Patent Document 6 discloses a compound having a quinoline ring and an acylthiourea structure as a compound particularly similar to the compound of the present invention.
- a compound in which the substituent at the 6-position of the quinoline ring is an aminocarbonyl group such as the compound of the present invention.
- the compound of the present invention, in which the substituent at the 6-position of the quinoline ring is an aminocarbonyl group is similar to the similar compound disclosed in Patent Document 6 (Comparative Compound 1), In the test, the inhibitory activity against c-Met phosphatase equivalent or higher was shown.
- the compound of the present invention does not show any toxicity (weight loss) even at the toxic dose of Comparative Compound 1, so that it is possible to increase the dose, and it is strong in an in vivo test using nude mice. Tumor reduction effect was also confirmed.
- the compound (I) of the present invention or a salt thereof has an excellent c-Met inhibitory action in an in vitro test, and the c-Met inhibitory action is a tumor in which c-Met is specifically expressed. Since it has high selectivity for cells and exhibits a strong tumor shrinking effect in in vivo tests, it is useful as an antitumor agent with reduced side effects.
- Diseases that can be treated by administering a drug containing the compound of the present invention include, for example, malignant tumors, head and neck cancer, esophageal cancer, stomach cancer, colon cancer, rectal cancer, liver cancer, gallbladder / bile duct cancer, biliary tract cancer, Pancreatic cancer, lung cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, kidney cancer, bladder cancer, prostate cancer, testicular tumor, bone / soft tissue sarcoma, leukemia, malignant lymphoma, multiple myeloma, skin cancer, brain tumor, Examples include mesothelioma.
- proliferative diseases caused by cell differentiation induction promotion of proliferation, such as psoriasis, proliferative with keratinization and inflammation, treatment of immune malignant skin diseases, immune diseases such as rheumatism, organ transplantation It is also useful as an immunosuppressive agent.
- substituent when “may have a substituent” for a certain structure, it may have one or more “substituents” at chemically possible positions on the structure. Means.
- the kind of substituents present in the structure, the number of substituents, and the substitution position are not particularly limited, and when two or more substituents are present, they may be the same or different.
- a halogen atom a hydroxyl group, a cyano group, a nitro group, a C 1-6 alkanoyl group, a C 1-6 alkyl group, a C 3-10 cycloalkyl group, a C 2-6 alkenyl group, C 1 -6 alkoxy group, amino group, C 1-6 alkylamino group, C 1-6 alkanoylamino group, C 1-6 alkylaminocarbonyl group, C 1-6 alkylsulfonyl group, C 6-14 aromatic hydrocarbon group A saturated or unsaturated heterocyclic group, a saturated or unsaturated heterocyclic carbonyl group, an oxo group, and the like. When the substituent is present, the number is typically 1 to 3.
- C 1-6 alkyl group” of the "optionally substituted C 1-6 alkyl group” represented by R 1 and R 2 are linear 1 to 6 carbon atoms Represents a chain-like or branched alkyl group, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group, n- Examples include a hexyl group and an isohexyl group.
- the “C 3-10 cycloalkyl group” of the “C 3-10 cycloalkyl group optionally having substituents” represented by R 1 and R 2 has 3 to 10 cycloalkyl groups are exemplified, and a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group are exemplified.
- C 6-14 aromatic hydrocarbon group of “ optionally substituted C 6-14 aromatic hydrocarbon group” represented by R 1 and R 2 is:
- An aromatic hydrocarbon group having 6 to 14 carbon atoms is exemplified, and examples thereof include a phenyl group and a naphthyl group.
- the “saturated or unsaturated heterocyclic group” of the “saturated or unsaturated heterocyclic group which may have a substituent” represented by R 1 and R 2 is an oxygen atom
- a 5- to 7-membered saturated heterocyclic ring having 1 or 2 nitrogen atoms such as pyrrolidinyl group, piperidinyl group, piperazinyl group, homopiperidinyl group, tetrahydrothienyl group and the like can be mentioned.
- the “nitrogen-containing heterocycle” of the “nitrogen-containing heterocycle optionally having substituent (s)” formed together with the nitrogen atom to which R 1 and R 2 are bonded is pyrrolidinyl
- nitrogen-containing saturated heterocycles such as a group, piperidinyl group, piperazinyl group and morpholino group, preferably pyrrolidinyl group and piperidinyl group.
- examples of the “C 1-6 alkyl group” represented by R 3 include the alkyl groups described above, preferably a C 1-3 alkyl group, and more preferably a methyl group.
- examples of the “halogen atom” represented by R 4 , R 5 and R 6 include a fluorine atom, a bromine atom, a chlorine atom and an iodine atom, preferably a fluorine atom and a chlorine atom. .
- R 4, "C 1-6 alkoxy group” represented by R 5 and R 6 "optionally substituted C 1-6 alkoxy group” include C 1 Represents a straight-chain or branched alkoxy group of -6, methoxy group, ethoxy group, n-propyloxy group, isopropyloxy group, n-butyloxy group, sec-butyloxy group, tert-butyloxy group, n-pentyloxy Group and n-hexyloxy group are exemplified, preferably C 1-3 alkoxy group, more preferably methoxy group.
- R 4 represented by R 5 and R 6 of the "optionally substituted C 1-6 alkylamino group", "C 1-6 alkylamino group"
- Examples include an amino group, sec-butylamino group, tert-butylamino group, n-pentylamino group, and n-hexylamino group.
- the “aromatic hydrocarbon group” of the “optionally substituted aromatic hydrocarbon group” represented by R 4 , R 5 and R 6 is the number of carbon atoms described above. 6 to 14 aromatic hydrocarbon groups, preferably phenyl group and naphthyl group.
- the “saturated or unsaturated heterocyclic ring” of the “saturated or unsaturated heterocyclic ring optionally having substituent (s)” represented by R 4 , R 5 and R 6 means the above-mentioned A saturated or unsaturated heterocyclic group is mentioned.
- a 5- to 7-membered saturated heterocyclic ring having 1 or 2 nitrogen atoms for example, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group and the like can be mentioned.
- Examples of the ring formed together with the phenyl ring to which R 5 and R 6 are bonded include naphthalene ring, quinoline ring, quinazoline ring, indole ring, benzimidazole ring, methylenedioxyphenyl ring, ethylenedioxyphenyl ring and the like. Can be mentioned.
- Examples of the halogen atom include the halogen atoms described above.
- Examples of the C 1-6 alkanoyl group include formyl group, acetyl group, propionyl group, butyryl group and the like.
- Examples of the C 1-6 alkyl group include the aforementioned C 1-6 alkyl groups.
- Examples of the C 3-10 cycloalkyl group include the aforementioned C 3-10 cycloalkyl groups.
- Examples of the C 2-6 alkenyl group include a vinyl group and a 2-propenyl group.
- Examples of the C 1-6 alkoxy group include the aforementioned C 1-6 alkoxy groups.
- Examples of the C 1-6 alkylamino group include the aforementioned C 1-6 alkylamino groups.
- Examples of the C 1-6 alkanoylamino group include amino groups substituted with the C 1-6 alkanoyl group.
- Examples of the C 1-6 alkylaminocarbonyl group include aminocarbonyl groups mono-substituted or di-substituted by the C 1-6 alkyl group.
- Examples of the C 1-6 alkylsulfonyl group include a sulfonyl group substituted by the C 1-6 alkyl group.
- Examples of the C 6-14 aromatic hydrocarbon group include the aforementioned C 6-14 aromatic hydrocarbon group.
- Examples of the saturated or unsaturated heterocyclic group include the saturated or unsaturated heterocyclic group described above.
- R 1 is preferably a hydrogen atom or a C 1-3 alkyl group, more preferably a hydrogen atom or a methyl group, and particularly preferably a hydrogen atom.
- R 2 includes a C 1-6 alkyl group which may have a substituent, a C 6-14 aromatic hydrocarbon group which may have a substituent, and a saturated which may have a substituent. Or an unsaturated heterocyclic group is preferable.
- the C 1-6 alkyl group represented by R 2 is more preferably a C 1-4 alkyl group, particularly preferably a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, or a sec-butyl group. .
- the substituent on the C 1-6 alkyl group represented by R 2 will be described in detail.
- substituents examples include a hydroxyl group, a C 3-10 cycloalkyl group, a C 1-6 alkoxy group, a C 1-6 alkylamino group, a C 1-6 alkanoylamino group, a C 1-6 alkylsulfonyl group, an aromatic group A group selected from a hydrocarbon group, a saturated or unsaturated heterocyclic group, a C 1-6 alkylaminocarbonyl group, and a saturated or unsaturated heterocyclic carbonyl group is preferable.
- the C 3-10 cycloalkyl group is more preferably a cyclohexyl group.
- the C 1-6 alkoxy group a C 1-3 alkoxy group is more preferable, and a methoxy group, an ethoxy group, and an isopropyloxy group are particularly preferable.
- the C 1-6 alkoxy group may further have a substituent, and the substituent is preferably a hydroxyl group.
- the C 1-6 alkylamino group a diethylamino group is more preferable.
- the C 1-6 alkanoylamino group an acetylamino group is more preferable.
- the C 1-6 alkylsulfonyl group a methylsulfonyl group is more preferable.
- the aromatic hydrocarbon group a phenyl group is more preferable.
- the saturated or unsaturated heterocyclic group is more preferably a 5- to 7-membered heterocyclic group having 1 to 4 nitrogen atoms and / or oxygen atoms.
- a pyrrolidinyl group, morpholino group, dioxolane group, tetrahydropyranyl group, pyridyl group And a tetrazolyl group are particularly preferred.
- the saturated or unsaturated heterocyclic group may further have a substituent, and the substituent is preferably a C 1-6 alkyl group (particularly a methyl group) or an oxo group.
- the C 1-6 alkylaminocarbonyl group an ethylaminocarbonyl group, a dimethylamino group, and a methylbutylamino group are more preferable.
- the C 1-6 alkylaminocarbonyl group may further have a substituent, and the substituent is preferably a hydroxyl group or a C 1-6 alkoxy group (particularly a methoxy group).
- the saturated or unsaturated heterocyclic carbonyl group a 5- to 7-membered saturated heterocyclic carbonyl group having 1 to 2 nitrogen atoms and / or oxygen atoms is more preferable, and a pyrrolidinylcarbonyl group and a morpholinocarbonyl group are particularly preferable. .
- the saturated or unsaturated heterocyclic carbonyl group may further have a substituent, and the substituent may be a halogen atom (particularly a fluorine atom) or a C 1-6 alkyl group (particularly a hydroxyl group).
- a methyl group is preferred.
- the C 6-14 aromatic hydrocarbon group represented by R 2 is more preferably a phenyl group.
- the substituent on the C 6-14 aromatic hydrocarbon group represented by R 2 will be described in detail.
- a C 1-6 alkyl group is preferable, and a methyl group is more preferable.
- the saturated or unsaturated heterocyclic group represented by R 2 is preferably a 5- to 7-membered saturated heterocyclic ring having 1 or 2 nitrogen atoms or sulfur atoms, more preferably a piperidinyl group, a homopiperidinyl group, or a tetrahydrothienyl group. preferable.
- the substituent on the saturated or unsaturated heterocyclic group represented by R 2 will be described in detail.
- the substituent is preferably a hydroxyl group, a C 1-6 alkanoyl group, a C 1-6 alkoxycarbonyl group, a C 1-6 alkylaminocarbonyl group, or an oxo group.
- the hydroxyl group, acetyl group, ethylaminocarbonyl group, tert group -A butyloxycarbonyl group and an oxo group are more preferable.
- R 2 includes methyl, methoxyethyl, morpholinoethyl, morpholinocarbonylmethyl, 2-hydroxy-n-butyl, 2-hydroxy-2-methyl-n-propyl, 1-hydroxy-n-butane
- the -2-yl group is particularly preferred, and the S form is particularly preferred in the case of the 1-hydroxy-n-butan-2-yl group.
- R 4 is preferably a halogen atom, particularly preferably a fluorine atom or a chlorine atom.
- the substitution position of R 4 is preferably the 2-position or the 3-position, and particularly preferably the 2-position.
- R 5 and R 6 are preferably a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group, or a C 1-3 alkoxy group.
- the substituent for the C 1-6 alkyl group represented by R 5 and R 6 is preferably a halogen atom, more preferably a fluorine atom. It is preferable that one of R 5 and R 6 is a hydrogen atom and the other is a hydrogen atom, a halogen atom, a trifluoromethyl group, or a methoxy group, and one of R 5 and R 6 is a hydrogen atom and the other is a hydrogen atom. More preferably, it is a halogen atom. When one of R 5 and R 6 is a hydrogen atom and the other is a halogen atom, the substitution position of R 6 is preferably the 2-position or the 4-position.
- Particularly preferred compounds in the present invention are the following acylthiourea compounds or salts thereof.
- the acylthiourea compound represented by the general formula (I) of the present invention includes solvates such as stereoisomers, optical isomers and hydrates.
- the acylthiourea compound represented by the general formula (I) of the present invention may be a salt, and the salt is preferably a pharmacologically acceptable salt.
- these salts include inorganic base salts, organic base salts, inorganic acid salts, organic acid salts, acidic amino acid salts, basic amino acid salts, and the like.
- examples of the salt of the inorganic base include alkali metal salts such as sodium salt and potassium salt, and alkaline earth metal salts such as magnesium salt and calcium salt.
- organic base salt examples include trimethylamine, triethylamine, pyridine, N-methylpyridine, N-methylpyrrolidone, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine and the like.
- inorganic acids include hydrochloric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid and the like.
- organic acids include formic acid, acetic acid, propionic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, maleic acid, lactic acid, malic acid, citric acid, tartaric acid, benzenesulfonic acid, p-toluenesulfonic acid, methane A sulfonic acid etc. can be illustrated.
- acidic amino acids include glutamic acid and aspartic acid
- basic amino acids include lysine, asparagine and ornithine.
- the acylthiourea compound represented by the general formula (I) of the present invention may be in the form of a pharmacologically acceptable prodrug.
- the pharmacologically acceptable prodrug is not limited as long as it can be converted into the general formula (I) by physiological conditions in vivo, for example, hydrolysis, oxidation, reduction reaction with gastric acid or enzyme. Examples thereof include ester type compounds such as methyl ester, ethyl ester, propyl ester, phenyl ester, carboxyoxymethyl ester, and ethoxycarbonyl ester that modify the carboxyl group.
- Representative examples of these prodrugs are compounds that can be converted into compound (I) under physiological conditions as described in Hirokawa Shoten 1990, “Pharmaceutical Development”, Volume 7, pages 163 to 198. Etc.
- the compound represented by the general formula (I) of the present invention or a salt thereof includes various hydrates, various solvates and crystal polymorphs thereof.
- the compound of the present invention can be produced according to the scheme described below.
- the raw materials required for the synthesis of the compound of the present invention can be easily produced by a commercially available method or a production method based on literature.
- the substituents in the scheme are the same as those defined in general formula (I).
- L represents a leaving group
- P represents a lower alkyl group and a benzyl group having a substituent.
- Other symbols are the same as defined in the general formula (I).
- Step 1 This step is a method for obtaining compound (I-2) from compound (I-1).
- a halide can be introduced as a leaving group L from a compound (I-1) that can be produced according to the description in International Publication No. 2002-032872 by using thionyl chloride, phosphorus oxychloride, or the like as a solvent.
- the temperature ranges from 0 ° C. to heating reflux, preferably from 80 ° C. to heating reflux.
- the reaction time is 0.1 to 100 hours, preferably 1 to 24 hours.
- N, N-dimethylformamide may be added as necessary, and the amount is 0.001 to 1 times, preferably 0.002 to 0.1 times the amount of Compound (I-1).
- a protecting group P is introduced by reacting alcohol P—OH in the presence of a base, Compound (I-2) can be obtained.
- the solvent is not particularly limited as long as it does not react with an acid halide, and a base may be used as a solvent.
- the alcohol P—OH include methanol, ethanol, tert-butanol, benzyl alcohol, 4-nitrobenzyl alcohol, 4-methoxybenzyl alcohol, and the like.
- the solvent amount can be used from 1 equivalent, preferably from 10 equivalents. Solvent amount.
- Bases include organic amines such as trimethylamine, triethylamine, tripropylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine, lutidine, collidine, sodium bicarbonate, sodium carbonate, methoxy Examples thereof include sodium, methoxypotassium, ethoxysodium, ethoxypotassium, tert-butoxypotassium and the like, and can be used in an amount of 1 to 200 times, preferably 1.5 to 100 times the amount of compound (I-1). .
- the temperature is from ⁇ 30 ° C. to reflux temperature, preferably 0 to 50 ° C.
- the reaction time is 0.1 to 100 hours, preferably 1 to 24 hours.
- Step 2 This step is a coupling reaction between compound (I-2) and compound (I-3), and is a reaction for obtaining compound (I-4).
- Compound (I-3) can be used in an amount of 1 to 100 equivalents, preferably 1.1 to 10 equivalents, of Compound (I-2).
- the coupling reaction is preferably carried out using a base, and the bases are trimethylamine, triethylamine, tripropylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine, lutidine, collidine.
- Inorganic bases such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate and the like can be used, and 1 to 100 equivalents can be used, and preferably 2 to 10 equivalents.
- the solvent used in this reaction is not particularly limited as long as it does not easily react with compounds (I-2), (I-3), (I-4), etc., and N, N-dimethylacetamide, diphenyl ether, chlorobenzene, 1,2-dichlorobenzene, N-methylpyrrolidin-2-one, dimethyl sulfoxide and the like can be mentioned, and these can be used alone or in combination.
- the reaction temperature is ⁇ 30 to 300 ° C., preferably 30 to 200 ° C.
- the reaction time is 0.1 to 100 hours, preferably 0.5 to 24 hours.
- Step 3 is a reaction for obtaining the compound (I-5) by reducing the nitro group of the compound (I-4).
- the conditions for the reduction reaction of the nitro group include a reaction using a reducing agent such as iron-ammonium chloride or iron-acetic acid. If the compound (I-4) does not contain chlorine, bromine, iodine, or a functional group such as benzyl, 4-nitrobenzyl or 4-methoxybenzyl as P, a catalytic hydrogenation reaction can also be used.
- the solvent is water, methanol, ethanol, 2-propanol, tetrahydrofuran, 1,4-dioxane, toluene, methylene chloride, chloroform, acetonitrile, N, N-dimethylformamide, N, N— Dimethylacetamide, N-methylpyrrolidin-2-one, dimethylsulfoxide and the like can be used singly or in combination.
- the reaction temperature is 0 to 200 ° C, preferably 30 to 100 ° C.
- the reaction time is 0.1 to 100 hours, preferably 0.5 to 24 hours.
- examples of the catalyst used include 5-10% palladium on carbon, palladium hydroxide, and the like, and can be used in an amount 0.01 to 10 times the amount of compound (I-4). The amount is preferably 0.02 to 5 times.
- the hydrogen source formic acid, ammonium formate, cyclohexene, dicyclohexene and the like can be used in an amount of 1 to 200 equivalents, preferably 1.1 to 100 equivalents. When hydrogen is used, it can be used at a pressure of 0.01 to 3.0 MPa, preferably 0.1 to 1.0 MPa.
- the solvent methanol, ethanol, tetrahydrofuran, ethyl acetate, N, N-dimethylformamide, dimethylformamide or the like can be used singly or in combination.
- Step 4 is a reaction for obtaining a compound (I-7) from a compound (I-5) using a thioisocyanate (I-6).
- the thioisocyanate (I-6) can be separately prepared from an acid halide or a carboxylic acid according to, for example, International Publication No. 2005-082855. These compounds (I-6) can be used in an amount of 1 to 100 equivalents, preferably 1.1 to 30 equivalents, relative to compound (I-5).
- the solvent used in this reaction is not particularly limited, and hexane, toluene, tetrahydrofuran, acetonitrile, N, N-dimethylformamide, N-methylpyrrolidin-2-one, methanol, ethanol, isopropanol, etc. are used singly or in combination. be able to.
- the reaction temperature is ⁇ 30 to 200 ° C., preferably 0 to 100 ° C.
- the reaction time is 0.1 to 100 hours, preferably 0.5 to 24 hours.
- Step 5 is a reaction for obtaining a carboxylic acid (I-8) from an ester (I-7).
- the ester can be converted to a carboxylic acid using basic conditions, acidic conditions, or catalytic hydrogenation reaction.
- sodium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide and the like can be used in an amount of 1 to 100 equivalents, preferably 1.1 to 30 equivalents.
- the solvent water, methanol, ethanol, isopropanol, tetrahydrofuran, 1,4-dioxane, N, N-dimethylformamide or the like can be used singly or in combination.
- tert-butyl or the like When tert-butyl or the like is used as P, deprotection under acidic conditions is preferable, and as the acid, hydrochloric acid, acetic acid, trifluoroacetic acid, sulfuric acid, tosylic acid and the like can be used as a solvent from 1 N, preferably From 2N to solvent amount.
- the solvent water, methanol, ethanol, isopropanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, methylene chloride, chloroform and the like can be used singly or in combination.
- P is a benzyl group, a 4-nitrobenzyl group, a 4-methoxybenzyl group or the like
- deprotection by a catalytic hydrogenation method using a catalyst is preferable.
- the catalyst to be used 5 to 10% palladium on carbon, palladium hydroxide and the like can be used in an amount of 0.01 to 10 times, preferably 0.02 to 5 times that of Compound (I-7).
- a hydrogen source formic acid, ammonium formate, cyclohexene, 1,4-dicyclohexene and the like can be used in an amount of 1 to 200 equivalents, preferably 1.1 to 100 equivalents, in addition to hydrogen.
- reaction temperature is -30 to 200 ° C, preferably 0 to 100 ° C.
- reaction time is 0.1 to 100 hours, preferably 0.5 to 24 hours.
- Step 6 This step is a condensation reaction of carboxylic acid (I-8) and amine (I-9).
- this step there are a method of obtaining compound (I) from carboxylic acid (I-8) via an acid halide, and a method of obtaining compound (I) using a commonly used condensing agent.
- (I-8) is converted to acid chloride using thionyl chloride, phosphorus oxychloride or the like in a solvent amount.
- the reaction temperature is ⁇ 30 to 200 ° C., preferably 0 to 100 ° C.
- the reaction time is 0.1 to 100 hours, preferably 1 to 24 hours.
- the compound (I) can be obtained by introducing amine (I-9) into the acid halide thus obtained.
- a base may be used as necessary.
- Examples of the base include trimethylamine, triethylamine, tripropylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine, lutidine, collidine and the like.
- Inorganic salts such as organic amines, sodium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, potassium tert-butoxide and the like can be mentioned.
- the amine (I-9) can be used in an amount of 1 to 100 equivalents, preferably 1.1 to 50 equivalents.
- solvent tetrahydrofuran, 1,4-dioxane, toluene, methylene chloride, chloroform, acetonitrile, N, N-dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide and the like are used.
- compound (I) can be obtained using a condensing agent.
- condensing agents N, N′-dicyclohexylcarbodiimide (DCC), N, N′-diisopropylcarbodiimide (DIC), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC), diphenylphosphoryl azide ( DPPA), benzotriazol-1-yl-oxytrisdimethylaminophosphonium hexafluorophosphate (BOP), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), 7-azabenzotriazol-1-yl Oxytrispyrrolidinophosphonium phosphate (PyAOP), bromotrispyrrolidinophosphonium hexafluorophosphate (BroP), chlorotris (pyrrolidin-1-yl) phosphor
- additives used at this time include 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), N-hydroxysuccinimide (HOSu), and the like.
- 100 equivalents can be used, preferably 1 to 10 equivalents.
- a base such as trimethylamine, triethylamine, tripropylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine, lutidine, collidine, etc. may be used.
- a base such as trimethylamine, triethylamine, tripropylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine, lutidine, collidine, etc.
- Amine (I-9) can be used in the same amount as described above, and the solvent is not particularly limited, but water, methanol, ethanol, 2-propanol, tetrahydrofuran, 1,4-dioxane, toluene, methylene chloride, chloroform Acetonitrile, N, N-dimethylformamide, N, N, -dimethylacetamide, dimethylsulfoxide and the like can be used.
- the reaction temperature is ⁇ 30 to 200 ° C., preferably 0 to 100 ° C.
- the reaction time is 0.1 to 100 hours, preferably 0.5 to 24 hours.
- compound (I) can also be obtained according to the fourth step after the amide is constructed according to the fifth and sixth steps of compound (I-5). Furthermore, when P is a methyl group, compound (I) can also be obtained according to the fourth step after constructing an amide from compound (I-5) by generally known aminolysis or the like.
- the compound of the present invention and the synthetic intermediate thus produced can be usually isolated and purified by known separation and purification means such as recrystallization, crystallization, distillation, column chromatography and the like.
- the compounds of the present invention and synthetic intermediates can usually form pharmacologically acceptable salts by known methods, and can be converted into each other.
- the compound (I) of the present invention When used as a medicine, it can be combined with a pharmaceutical carrier as necessary, and various administration forms can be adopted depending on the purpose of prevention or treatment. Any of injections, suppositories, ointments, patches and the like may be used, and oral preparations are preferably employed. Each of these dosage forms can be produced by a conventional formulation method known to those skilled in the art.
- the pharmaceutical carrier various organic or inorganic carrier substances commonly used as pharmaceutical materials are used, and excipients, binders, disintegrants, lubricants, coloring agents in solid preparations, solvents in liquid preparations, dissolution aids, It is blended as a suspending agent, isotonic agent, buffer, soothing agent and the like.
- formulation additives such as preservatives, antioxidants, colorants, sweeteners, stabilizers and the like can be used as necessary.
- an excipient When preparing an oral solid preparation, an excipient, if necessary, an excipient, a binder, a disintegrant, a lubricant, a coloring agent, a flavoring / flavoring agent, etc. are added to the compound of the present invention. Tablets, coated tablets, granules, powders, capsules and the like can be produced by the method.
- excipient examples include lactose, sucrose, D-mannitol, glucose, starch, calcium carbonate, kaolin, microcrystalline cellulose, and anhydrous silicic acid.
- binder examples include water, ethanol, 1-propanol, 2-propanol, simple syrup, glucose solution, ⁇ -starch solution, gelatin solution, D-mannitol, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropyl starch, methylcellulose, ethylcellulose, Shellac, calcium phosphate, polyvinylpyrrolidone and the like can be mentioned.
- Examples of the disintegrant include dry starch, sodium alginate, agar powder, sodium hydrogen carbonate, calcium carbonate, sodium lauryl sulfate, stearic acid monoglyceride, and lactose.
- Examples of the lubricant include purified talc, sodium stearate, magnesium stearate, borax, and polyethylene glycol.
- Examples of the colorant include titanium oxide and iron oxide.
- Examples of the flavoring / flavoring agent include sucrose, orange peel, citric acid, tartaric acid and the like.
- a liquid preparation, a syrup, an elixir and the like can be produced by a conventional method by adding a flavoring agent, a buffer, a stabilizer, a flavoring agent and the like to the compound of the present invention.
- the flavoring / flavoring agent may be those listed above
- examples of the buffer include sodium citrate
- examples of the stabilizer include tragacanth, gum arabic, and gelatin.
- an enteric coating or a coating can be applied to the oral preparation by a known method for the purpose of sustaining the effect.
- examples of such a coating agent include hydroxypropylmethylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, polyoxyethylene glycol, Tween 80 (registered trademark), and the like.
- a pH adjuster, buffer, stabilizer, tonicity agent, local anesthetic, etc. are added to the compound of the present invention, and subcutaneous, intramuscular and intravenous injections are prepared by conventional methods.
- the pH adjuster and buffer include sodium citrate, sodium acetate, and sodium phosphate.
- the stabilizer include sodium pyrosulfite, EDTA, thioglycolic acid, thiolactic acid and the like.
- local anesthetics include procaine hydrochloride and lidocaine hydrochloride.
- isotonic agents include sodium chloride, glucose, D-mannitol, glycerin and the like.
- a formulation carrier known in the art such as polyethylene glycol, lanolin, cocoa butter, fatty acid triglyceride, etc., and an interface such as Tween 80 (registered trademark) are added to the compound of the present invention as necessary. After adding an activator etc., it can manufacture by a conventional method.
- bases, stabilizers, wetting agents, preservatives and the like that are usually used for the compound of the present invention are blended as necessary, and mixed and formulated by a conventional method.
- the base include liquid paraffin, white petrolatum, white beeswax, octyldodecyl alcohol, paraffin and the like.
- the preservative include methyl paraoxybenzoate, ethyl paraoxybenzoate, and propyl paraoxybenzoate.
- the amount of the compound of the present invention to be formulated in each of the above dosage unit forms is not constant depending on the symptoms of the patient to which the compound is to be applied or the dosage form thereof, but is generally about an oral dosage form per dosage unit form. 0.05 to 1,000 mg, about 0.01 to 500 mg for injections, and about 1 to 1,000 mg for suppositories are desirable.
- the daily dose of the drug having the above-mentioned dosage form varies depending on the patient's symptoms, body weight, age, sex, etc., and cannot be determined unconditionally.
- the dose may be 5,000 mg, preferably 0.1 to 1,000 mg, and is preferably administered once a day or divided into 2 to 3 times a day.
- Phenylacetyl chloride (1.10 mL) and potassium thiocyanate (1.21 g) were dissolved in acetonitrile (15 mL) and stirred at 70 ° C. for 2 hours.
- the reaction mixture was cooled to room temperature, concentrated under reduced pressure, and then partitioned between saturated aqueous sodium hydrogen carbonate solution (100 mL) and ethyl acetate (50 mL). The organic layer was washed with saturated brine (100 mL), dried over sodium sulfate, and concentrated under reduced pressure to obtain phenylacetylthioisocyanate.
- Example 2 As in the synthesis of Example 1, compound 1e (20 mg), 40% aqueous methylamine solution (5 ⁇ L) and DTMMM ⁇ n hydrate (22 mg) are dissolved in tetrahydrofuran (1 mL) and stirred at 30 ° C. for 1 hour. Gave the title compound 6 (18.4 mg, 96% yield).
- Example 2 Similarly to the synthesis of Example 1, compound 1e (20 mg), 2-methoxyethyleneamine (6 mg), DTMMM ⁇ n hydrate (22 mg) are dissolved in ethanol (1 mL) and stirred at 30 ° C. for 1 hour. Gave the title compound 7 (17.3 mg, 83% yield).
- Example 2 Similar to the synthesis of Example 1, from compound 1e (304 mg), 2-amino-1- (pyrrolidin-1-yl) ethanone hydrochloride (120 mg), triethylamine (235 ⁇ L), DTMMM ⁇ n hydrate (186 mg) The title compound 17 (220 mg, yield 64%) was obtained.
- 4-Fluorophenylacetic acid (900 mg) was dissolved in thionyl chloride (5 mL) and heated to reflux for 2 hours. The reaction system was concentrated under reduced pressure, and azeotroped with toluene to give crude 4-fluorophenylacetic acid chloride. . This was dissolved in acetonitrile (20 mL), potassium thioisocyanate (851 mg) was added, and the mixture was stirred at 70 ° C. for 5 hr. The reaction solution was cooled to room temperature and concentrated under reduced pressure, and then partitioned between saturated aqueous sodium hydrogen carbonate solution (100 mL) and ethyl acetate (50 mL).
- Example 2 Similarly to the synthesis of Example 1, from the compound 1e (35.3 mg), the compound 20b (14.3 mg), triethylamine (22.7 ⁇ L), DTMMM ⁇ n hydrate (21.6 mg), the title compound 20 (15 0.1 mg, yield 37%).
- Example 2 Similarly to the synthesis of Example 1, from the compound 19b (25.0 mg), 1-amino-2-butanol (10.6 ⁇ L), DTMMM ⁇ n hydrate (14.8 mg), the title compound 23 (14.2 mg) was obtained. Yield 53%).
- Example 28 4- (2-Fluoro-4- (3- (2-phenylacetyl) thioureido) phenoxy) -7-methoxy-No-tolylquinoline-6-carboxamide (28) Similar to the synthesis of Compound 1, Compound 1e (32 mg), orthotoluidine (7.59 ⁇ L), and DTMMM ⁇ n hydrate (19.6 mg) gave the title compound 28 (19.8 mg, 56% yield). It was.
- Example 30 4- (2-Fluoro-4- (3- (2-phenylacetyl) thioureido) phenoxy) -N- (2-hydroxy-2- (2-methyl-2H-tetrazol-5-yl) ethyl) -7- Methoxyquinoline-6-carboxamide (30) Similar to the synthesis of Compound 1, Compound 1e (30.0 mg), 2-amino-1- (2-methyl-2H-tetrazol-5-yl) ethanol (12.7 mg), DTMMM ⁇ n hydrate (19 From 7 mg) to give the title compound 30 (31.2 mg, 83% yield).
- Example 32 4- (2-Fluoro-4- (3- (2-phenylacetyl) thioureido) phenoxy) -N- (1-hydroxytetrahydrothiophen-3-yl) -7-methoxyquinoline-6-carboxamide (32) Similar to the synthesis of Compound 1, Compound 1e (25.7 mg), 4-aminotetrahydrothiophene-3-ol hydrochloride (16.9 mg), DMTMM ⁇ n hydrate (11.5 mg), triethylamine (14.2 ⁇ L) ) Gave the title compound 32 (30.2 mg, 93% yield).
- Example 34 (S) -4- (2-Fluoro-4- (3- (2-phenylacetyl) thioureido) phenoxy) -N- (2- (2- (hydroxymethyl) pyrrolidin-1-yl) -2-oxoethyl) -7-methoxyquinoline-6-carboxamide (34) Similar to the synthesis of Compound 1, compound 33b (50 mg), (S) -pyrrolidin-2-ylmethanol (11 ⁇ L), DTMMM ⁇ n hydrate (30 mg), N-methylmorpholine (24 ⁇ L), and the title compound 34 (32 mg, 60% yield) was obtained.
- Example 35 N- (2- (ethyl (2-hydroxy-2-methylpropyl) amino) -2-oxoethyl) -4- (2-fluoro-4- (3- (2-phenylacetyl) thioureido) phenoxy) -7- Methoxyquinoline-6-carboxamide (35) Similar to the synthesis of Compound 1, from Compound 33b (35.0 mg), 1- (ethylamino) -2-methylpropan-2-ol (17.1 mg), DTMMM ⁇ n hydrate (19.4 mg), The title compound 35 (12.3 mg, 32% yield) was obtained.
- Example 36 tert-Butyl 2- (4- (2-Fluoro-4- (3- (2-phenylacetyl) thioureido) phenoxy) -7-methoxyquinoline-6-carboxamide) propanoate (36a) Similarly to the synthesis of Compound 1, Compound 36a (109 mg, 87% yield) was obtained from Compound 1e (100 mg), Alanine tertbutyl ester hydrochloride (47 mg) and DTMMM ⁇ n hydrate (71 mg).
- Example 37 4- (2-Fluoro-4- (3- (2- (4-fluorophenyl) acetyl) thioureido) phenoxy) -7-methoxy-N- (2-morpholinoethyl) quinoline-6-carboxamide (37)
- the title compound 37 (462 mg, 73% yield) was obtained from the compound 19b (523 mg), 2-morpholinoethanamine (171 mg) and DTMMM ⁇ n hydrate (360 mg).
- Example 38 (S) -4- (2-Fluoro-4- (3- (2- (4-fluorophenyl) acetyl) thioureido) phenoxy) -N- (1-hydroxybutan-2-yl) -7-methoxyquinoline- 6-Carboxamide (38) Similar to the synthesis of Example 1, compound 19b (50 mg), (S) -2-aminobutan-1-ol (12 ⁇ L), DTMMM ⁇ n hydrate (34 mg), the title compound 38 (25 mg, yield 45) %).
- Example 39 Methyl 4- (2-fluoro-4-nitrophenoxy) -7-methoxyquinoline-6-carboxylate (39a) Methyl 4-chloro-7-methoxyquinoline-6-carboxylate (1.00 g), 2-fluoro-4-nitrophenol (936 mg), N, N-diisopropylethylamine (1) synthesized in accordance with International Publication WO2005080377 .35 mL) gave Compound 39a (1.38 g, 93% yield).
- Example 41 (S) -4- (4-Amino-2-fluorophenoxy) -N- (1-hydroxybutan-2-yl) -7-methoxyquinoline-6-carboxamide (41a) Similar to the synthesis of compound 1, compound 41a (297 mg, 81% yield) was obtained from compound 39c (300 mg), DMTMM ⁇ n hydrate (329 mg), and (S) -2-aminobutan-1-ol (113 ⁇ L). Got.
- Example 42 4- (4-Amino-2-fluorophenoxy) -N- (2-hydroxy-2-methylpropyl) -7-methoxyquinoline-6-carboxamide (42a) Similarly to the synthesis of compound 1, compound 42a (66.3 mg, yield 53) was obtained from 39c (103 mg), DTMMM ⁇ n hydrate (104 mg) and 1-amino-2-methylpropan-2-ol (42 mg). %).
- Example 43 (S) -4- (4- (3- (2- (4-chlorophenyl) acetyl) thioureido) -2-fluorophenoxy) -N- (1-hydroxybutan-2-yl) -7-methoxyquinoline-6 Carboxamide (43)
- the title compound 43 (29.9 mg, 31% yield) was obtained from the compound 41a (63.0 mg) and 4-chlorophenylacetylthioisocyanate (50.1 mg).
- Example 44 4- (4- (3- (2- (2,6-difluorophenyl) acetyl) thioureido) -2-fluorophenoxy) -7-methoxyquinoline-6-carboxylic acid (44a) Similar to the synthesis of Compound 1d, Compound 39c (98 mg), 2,6-difluorophenylacetylthioisocyanate (128 mg) and N, N-dimethylacetamide (1.5 mL), toluene (1.5 mL), ethanol (300 ⁇ L) Compound 44a (143 mg, 89% yield) was obtained as a crude product.
- Example 45 4- (4- (3- (2- (2,6-difluorophenyl) acetylthioureido) -2-fluorophenoxy) -N- (2-hydroxy-2-methylpropyl) -7-methoxyquinoline-6- Carboxamide (45) Similar to the synthesis of Compound 1, from Compound 44a (101 mg), N, N-dimethylacetamide (600 ⁇ L), DTMMM ⁇ n hydrate (68 mg), 1-amino-2-methylpropan-2-ol (31 mg) The title compound 45 (74 mg, yield 65%) was obtained.
- Example 46 4- (4-Amino-2-fluorophenoxy) -7-methoxy-N-methylquinoline-6-carboxamide (46a)
- Compound 39b 100 mg was dissolved in N-methylpiperidin-2-one (250 ⁇ L), 40% methylamine methanol solution (250 ⁇ L) was added, and the mixture was stirred at 40 ° C. for 16 hours. Water was added to the reaction solution, and the resulting precipitate was collected by filtration to give compound 46a (63.7 mg, yield 64%).
- Example 47 4- (2-Fluoro-4- (3- (2- (4-trifluoromethylphenyl) acetyl) thioureido) phenoxy) -7-methoxy-N-methylquinoline-6-carboxamide (47) Similarly to the synthesis of Compound 1d, the title compound 47 (41.2 mg, 48% yield) was obtained from Compound 46a (50.0 mg) and 4-trifluoromethylphenylacetylisothiocyanate (53.9 mg).
- Example 48 Methyl 4- (2-chloro-4-nitrophenoxy) -7-methoxyquinoline-6-carboxylate (48a) Similar to the synthesis of Compound 1a, methyl 4-chloro-7-methoxyquinoline-6-carboxylate (350 mg), 2-chloro-4-nitrophenol (240 mg), N, N-diisopropylethylamine (484 ⁇ L), N- Compound 48a (130 mg, yield 24%) was obtained from methylpyrrolidin-2-one (1.5 mL).
- Example 49 Methyl 4- (3-fluoro-4-nitrophenoxy) -7-methoxyquinoline-6-carboxylate (49a) Similar to the synthesis of compound 1a, methyl 4-chloro-7-methoxyquinoline-6-carboxylate (300 mg), 3-fluoro-4-nitrophenol (225 mg), N, N-diisopropylethylamine (415 ⁇ L), N- Compound 49a (112 mg, 25% yield) was obtained from methylpyrrolidin-2-one (1.5 mL).
- Example 50 4- (2-Fluoro-4- (3- (2-phenylacetyl) thioureido) phenoxy) -7-methoxy-N, N-dimethylquinoline-6-carboxamide (50)
- the title compound 50 (256 mg, 91% yield) was obtained from Compound 1e (285 mg), 50% aqueous dimethylamine solution (147 ⁇ L) and DTMMM ⁇ n hydrate (174 mg).
- Example 52 N- (3-Fluoro-4- (6- (3-hydroxypyrrolidin-1-carbonyl) -7-methoxyquinolin-4-yloxy) phenylcarbamothioyl) -2-phenylacetamide (52) Similar to the synthesis of Compound 1, from Compound 1e (20.0 mg), Pyrrolidin-3-ol (9.3 mg), DTMMM ⁇ n hydrate (11.8 mg), the title compound 52 (15.0 mg, yield) 71%).
- Comparative Example 1 4- (2-Fluoro-4- (3- (2-phenylacetyl) thioureido) phenoxy) -6,7-dimethoxy-quinoline-6-carboxamide (Comparative Compound 1) It was synthesized according to the method described in International Publication No. 2006-104161.
- Test Example 1 c-Met inhibitory activity measurement test (in vitro) The inhibitory activity against c-Met kinase was measured according to the following method. Method A) Assay method using AlphaScreen Clin Cancer Res. vol. 8, (2), pp620-7 (2002), a biotinylated peptide containing a phosphorylation site Tyr402 of Pyk2 reported as a substrate in vivo, and a reaction buffer (60 mM HEPES pH 7.5, 5 mM).
- c-Met (08-051, Carna bio Co., Ltd) was added at a final concentration of 20 ⁇ M. And allowed to react at room temperature for 20 minutes. The reaction was stopped by adding EDTA to a final concentration of 50 mM.
- Method B Assay method using DeskTop Profiler Reaction with addition of dephosphorylating enzyme inhibitor cocktail (PHOSTOP, # 4906837, Roche) and proteolytic enzyme inhibitor cocktail (Complete, Mini, EDTA-free, # 1836170, Roche) use buffer (100mM HEPES pH7.5,10mM MgCl 2, 0.003 % Brij-35,0.04% Tween, 1mM DTT) was prepared.
- the reaction buffer contains recombinant c-Met (in-house purified product), final labeled concentration of 1.5 ⁇ M fluorescently labeled c-Met substrate peptide (FL-Peptide2, # 760346, Caliper LifeSciences) and final concentration of 43 ⁇ M.
- ATP was added and reacted at 28 ° C. for 90 minutes. The reaction was stopped by adding EDTA to a final concentration of 10 mM.
- EDTA EDTA
- the compound concentration capable of suppressing the generation of phosphorous oxide by 50% is defined as IC 50 value ( ⁇ M) and shown in the following table.
- RPMI 1640 manufactured by Wako Pure Chemical Industries
- FBS or DMEM medium manufactured by Nacalai Tesque
- the compound of the present invention and Comparative Compound 1 are dissolved in dimethyl sulfoxide to a concentration of 30 mM, and further, RPMI1640 or DMEM medium containing 10% FBS is used, and the final concentration of the test compound is 60, 20, 6, 2, respectively. , 0.6, and 0.2 ⁇ M.
- 0.1 mL of this was added to each well of the culture plate for NUGC4 cells and cultured at 37 ° C. for 3 days in a 5% carbon dioxide-containing incubator. After culturing, 20 ⁇ L of 25% glutaraldehyde aqueous solution (manufactured by Nacalai Tesque) was added to each well and allowed to stand at room temperature for 20 minutes to fix the cells.
- Inhibition rate (%) (C ⁇ T) / C ⁇ 100 T: Absorbance of well to which test compound was added C: Absorbance of well to which test compound was not added
- the compound of the present invention exhibits a strong antiproliferative activity against NUGC4 (c-Met overexpression / highly activated human gastric cancer strain), which is higher than that of Comparative Compound 1, and thus has an excellent anti-tumor activity. It was confirmed to have tumor activity.
- Tumor cells with low expression of c-Met HCT-116
- normal cells HAOSMC (human aortic smooth muscle cells), HMEC (human skin microvascular endothelial cells)
- the IC 50 for these cell lines was 15 to 24 ⁇ M for Comparative Compound 1, whereas most of the compounds of the present invention were 30 ⁇ M or more, and the same for Comparative Compound 1 for the low c-Met expression strain. Or it was confirmed that the cell growth inhibitory activity below it was shown. That is, the discrepancy between the cell growth inhibitory effect on cancer cells overexpressing c-Met and the cell growth inhibitory effect on cells with low c-Met expression or normal cells is significantly greater than that of Comparative Compound 1. From the results, it was confirmed that the compound of the present invention has excellent selective cell growth inhibitory activity.
- Test Example 3 Dose setting test for evaluation of antitumor effect (in vivo)
- the maximum tolerated dose was calculated using the transition as an evaluation index.
- the weight change rate (Body weight change; BWC%) of the mouse during the administration period was calculated, and when the average BWC of each compound administration group showed a decrease of 10% or more, it was judged as the dose of toxicity due to the drug, As the dose, a dose that was two times lower than the toxic dose was set.
- Test Example 4 Evaluation of antitumor effect using human gastric cancer cell line (NUGC4) subcutaneous transplantation model (in vivo)
- NUGC4 human stomach cancer cells (obtained from ATCC) were transplanted subcutaneously into nude mice, and the tumor volume of nude mice in which the tumor engrafted reached about 100 to 300 mm 3 , the average tumor volume of each group was By random stratification so as to be uniform, 5 to 6 animals per group were allocated (day 1), and the compound of the present invention and comparative compound 1 were orally administered once a day for 14 days.
- the administration dose was 100 mg / kg of the maximum tolerated dose (maximum dose at which weight loss during the administration period was less than 10%) in Comparative Compound 1 in 14 days, which is the administration period of this test. / Day, 400 mg / kg / day was used in the compound of the present invention.
- the relative tumor volume (RTV) with the tumor volume at the time of grouping as 1 was calculated as the tumor growth rate according to the following formula, The transition of the average value of the RTV of the individual is shown in FIG.
- RTV (tumor volume on the day of tumor volume measurement) / (tumor volume at the time of grouping)
- the compound of the present invention was equivalent to or higher than the comparative compound 1 in the inhibitory effect of c-Met (Test Example 1), but was excellent in selectivity of the cell growth inhibitory effect (Test Example 2). It was suggested that the toxicity to non-target cells including normal cells is reduced. From the results of the dose setting test for nude mice, the compound of the present invention does not show a decrease in body weight even at a dose (400 mg / kg) exceeding the dose of toxicity of Comparative Compound 1 (200 mg / kg), and the compound has low toxicity. (Test Example 3). Furthermore, the compound of the present invention showed an excellent antitumor effect of tumor reduction as a result of administration of a dose (400 mg / kg) significantly exceeding the maximum tolerated dose (100 mg / kg) of Comparative Compound 1. (Test Example 4).
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Description
本発明は、このような知見に基づき完成されたものである。
R3は、C1-6アルキル基を示し;
R4、R5及びR6は、同一又は異なって、水素原子、ハロゲン原子、置換基を有していてもよいC1-6アルキル基、C1-6アルコキシ基、C1-6アルキルアミノ基、置換基を有していてもよい芳香族炭化水素基、又は置換基を有していてもよい飽和又は不飽和複素環基を示すか、R5及びR6は結合するフェニル環と一緒になって環を形成していてもよい。)
で表されるアシルチオウレア化合物又はその塩を提供するものである。
また、本発明は、上記一般式(I)で表されるアシルチオウレア化合物又はその塩を有効成分とする医薬を提供するものである。
また、本発明は、上記一般式(I)で表されるアシルチオウレア化合物又はその塩、及び薬学的に許容される担体を含有する医薬組成物を提供するものである。
また本発明は、抗腫瘍剤製造のための、上記一般式(I)で表されるアシルチオウレア化合物又はその塩の使用を提供するものである。
さらに本発明は、上記一般式(I)で表される化合物アシルチオウレア化合物又はその塩の有効量を投与することを特徴とする癌治療法を提供するものである。
本発明化合物を含有する薬剤を投与することにより治療できる疾病としては、例えば悪性腫瘍の場合、頭頚部癌、食道癌、胃癌、結腸癌、直腸癌、肝臓癌、胆嚢・胆管癌、胆道癌、膵臓癌、肺癌、乳癌、卵巣癌、子宮頚癌、子宮体癌、腎癌、膀胱癌、前立腺癌、精巣腫瘍、骨・軟部肉腫、白血病、悪性リンパ腫、多発性骨髄腫、皮膚癌、脳腫瘍、中皮腫等が挙げられる。また、特に細胞の分化誘導、増殖を促進させることによる増殖性の疾患、例えば、乾癬等角化や炎症を伴う増殖性、免疫性の悪性皮膚疾患の治療、リウマチ等免疫性疾患、臓器移植時の免疫抑制剤としても有用である。
当該構造に存在する置換基の種類、置換基の個数、置換位置は特に限定されず、2個以上の置換基が存在する場合には、それらは同一であっても異なっていてもよい。「置換基」としては、ハロゲン原子、ヒドロキシル基、シアノ基、ニトロ基、C1-6アルカノイル基、C1-6アルキル基、C3-10シクロアルキル基、C2-6アルケニル基、C1-6アルコキシ基、アミノ基、C1-6アルキルアミノ基、C1-6アルカノイルアミノ基、C1-6アルキルアミノカルボニル基、C1-6アルキルスルホニル基、C6-14芳香族炭化水素基、飽和又は不飽和複素環基、飽和又は不飽和複素環カルボニル基、オキソ基等が例示され、前記置換基が存在する場合、その個数は典型的には1~3個である。
R2で表されるC1-6アルキル基は、C1-4アルキル基がより好ましく、メチル基、エチル基、n-プロピル基、イソプロピル基、n-ブチル基、sec-ブチル基が特に好ましい。ここで、R2で表されるC1-6アルキル基上の置換基について詳細に説明する。該置換基としては、ヒドロキシル基、C3-10シクロアルキル基、C1-6アルコキシ基、C1-6アルキルアミノ基、C1-6アルカノイルアミノ基、C1-6アルキルスルホニル基、芳香族炭化水素基、飽和又は不飽和複素環基、C1-6アルキルアミノカルボニル基、飽和又は不飽和複素環カルボニル基から選ばれる基が好ましい。C3-10シクロアルキル基としては、シクロヘキシル基がより好ましい。C1-6アルコキシ基としてはC1-3アルコキシ基がより好ましく、メトキシ基、エトキシ基、イソプロピルオキシ基が特に好ましい。該C1-6アルコキシ基はさらに置換基を有していてもよく、置換基としてはヒドロキシル基が好ましい。C1-6アルキルアミノ基としては、ジエチルアミノ基がより好ましい。C1-6アルカノイルアミノ基としては、アセチルアミノ基がより好ましい。C1-6アルキルスルホニル基としては、メチルスルホニル基がより好ましい。芳香族炭化水素基としては、フェニル基がより好ましい。飽和又は不飽和複素環基としては、窒素原子及び/又は酸素原子を1~4個有する5~7員の複素環基がより好ましく、ピロリジニル基、モルホリノ基、ジオキソラン基、テトラヒドロピラニル基、ピリジル基、テトラゾリル基が特に好ましい。該飽和又は不飽和複素環基はさらに置換基を有していてもよく、置換基としてはC1-6アルキル基(特にメチル基)、オキソ基が好ましい。C1-6アルキルアミノカルボニル基としては、エチルアミノカルボニル基、ジメチルアミノ基、メチルブチルアミノ基がより好ましい。該C1-6アルキルアミノカルボニル基はさらに置換基と有していてもよく、置換基としてはヒドロキシル基、C1-6アルコキシ基(特にメトキシ基)が好ましい。飽和又は不飽和複素環カルボニル基としては、窒素原子及び/又は酸素原子を1~2個有する5~7員の飽和複素環カルボニル基がより好ましく、ピロリジニルカルボニル基、モルホリノカルボニル基が特に好ましい。該飽和又は不飽和複素環カルボニル基はさらに置換基を有していてもよく、置換基としてはハロゲン原子(特にフッ素原子)、ヒドロキシル基を有していてもよいC1-6アルキル基(特にメチル基)が好ましい。
R5及びR6の一方が水素原子であり、他方が水素原子、ハロゲン原子、トリフルオロメチル基、又はメトキシ基である場合が好ましく、R5及びR6の一方が水素原子、他方が水素原子、ハロゲン原子である場合がより好ましい。R5及びR6の一方が水素原子、他方がハロゲン原子である場合には、R6の置換位置としては2位、又は4位が好ましい。
・4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-メチルキノリン-6-カルボキサミド
・4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(メトキシエチル)キノリン-6-カルボキサミド
・4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(2-モルホリノエチル)キノリン-6-カルボキサミド
・4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(2-モルホリノ-2-オキソエチル)キノリン-6-カルボキサミド
・4-(2-フルオロ-4-(3-(2-(4-フルオロフェニル)アセチル)チオウレイド)フェノキシ)-N-(2-ヒドロキシブチル)-7-メトキシキノリン-6-カルボキサミド
・4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-N-(2-ヒドロキシ-2-メチルプロピル)-7-メトキシキノリン-6-カルボキサミド
・(S)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-N-(1-ヒドロキシブタン-2-イル)-7-メトキシキノリン-6-カルボキサミド
・4-(2-フルオロ-4-(3-(2-(4-フルオロフェニル)アセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(2-モルホリノエチル)キノリン-6-カルボキサミド
・(S)-4-(2-フルオロ-4-(3-(2-(4-フルオロフェニル)アセチル)チオウレイド)フェノキシ)-N-(1-ヒドロキシブタン-2-イル)-7-メトキシキノリン-6-カルボキサミド
・(S)-4-(2-フルオロ-4-(3-(2-(2-フルオロフェニル)アセチル)チオウレイド)フェノキシ)-N-(1-ヒドロキシブタン-2-イル)-7-メトキシキノリン-6-カルボキサミド
・(S)-4-(4-(3-(2-(4-クロロフェニル)アセチル)チオウレイド)-2-フルオロフェノキシ)-N-(1-ヒドロキシブタン-2-イル)-7-メトキシキノリン-6-カルボキサミド
本発明の一般式(I)で表されるアシルチオウレア化合物は、塩であってもよく、塩としては薬理学的に許容される塩が好ましい。これらの塩としては、無機塩基の塩、有機塩基の塩、無機酸との塩、有機酸との塩、酸性アミノ酸との塩、塩基性アミノ酸との塩等が挙げられる。
具体的には、無機塩基の塩としてはナトリウム塩、カリウム塩等アルカリ金属塩が例示でき、また、マグネシウム塩、カルシウム塩等アルカリ土類金属塩が例示できる。
有機塩基の塩としては、トリメチルアミン、トリエチルアミン、ピリジン、N-メチルピリジン、N-メチルピロリドン、エタノールアミン、ジエタノールアミン、トリエタノールアミン、ジシクロヘキシルアミン等が例示できる。
また、無機酸の例としては、塩酸、硫酸、臭化水素酸、ヨウ化水素酸、硝酸、リン酸等が例示できる。
有機酸の例としては、ギ酸、酢酸、プロピオン酸、マロン酸、コハク酸、グルタル酸、フマル酸、マレイン酸、乳酸、リンゴ酸、クエン酸、酒石酸、ベンゼンスルホン酸、p-トルエンスルホン酸、メタンスルホン酸等が例示できる。
また、酸性アミノ酸の例としては、グルタミン酸、アスパラギン酸等が例示でき、塩基性アミノ酸の例としては、リジン、アスパラギン、オルニチン等が例示できる。
本工程は化合物(I-1)から化合物(I-2)を得る方法である。具体的には国際公開2002-032872号公報記載に準じて製造可能な化合物(I-1)から塩化チオニル、オキシ塩化りんなどを溶媒として用いることでハライドを脱離基Lとして導入できる。温度は0℃から加熱還流の温度であり、好ましくは80℃から加熱還流である。反応時間は0.1から100時間であり、好ましくは1から24時間である。必要に応じてN,N-ジメチルホルムアミドを添加してもよく、化合物(I-1)の0.001から1倍量であり、好ましくは0.002から0.1倍量である。
本工程は化合物(I-2)と化合物(I-3)とのカップリング反応であり、化合物(I-4)を得る反応である。化合物(I-3)は化合物(I-2)の1から100当量用いることができ、好ましくは1.1から10当量である。カップリング反応には塩基を用いて行うのが好ましく、塩基としてはトリメチルアミン、トリエチルアミン、トリプロピルアミン、ジイソプロピルエチルアミン、N-メチルモルホリン、ピリジン、4-(N,N-ジメチルアミノ)ピリジン、ルチジン、コリジン等の有機アミン類や炭酸水素ナトリウム、炭酸ナトリウム、炭酸カリウム、炭酸セシウム等の無機塩基が挙げられ、1から100当量用いることができ、好ましくは2から10当量である。本反応で用いる溶媒は化合物(I-2)、(I-3)、(I-4)などと容易に反応する溶媒でなければ特に制限はなく、N,N-ジメチルアセトアミド、ジフェニルエーテル、クロロベンゼン、1,2-ジクロロベンゼン、N-メチルピロリジン-2-オン、ジメチルスルホキシドなどが挙げられ、これらを単一又は混合して用いることができる。反応温度は-30から300℃であり、好ましくは30から200℃である。反応時間は0.1から100時間であり、好ましくは0.5から24時間である。
本工程は化合物(I-4)のニトロ基を還元して化合物(I-5)を得る反応である。ニトロ基の還元反応の条件としては鉄-塩化アンモニウム、鉄-酢酸などの還元剤を用いる反応が挙げられる。化合物(I-4)中に塩素、臭素、ヨウ素や、Pとしてベンジル、4-ニトロベンジル、4-メトキシベンジルなどの官能基が含まれていなければ接触水素添加反応を用いることもできる。鉄-塩化アンモニウムを用いた場合、溶媒としては水、メタノール、エタノール、2-プロパノール、テトラヒドロフラン、1,4-ジオキサン、トルエン、塩化メチレン、クロロホルム、アセトニトリル、N,N-ジメチルホルムアミド、N,N-ジメチルアセトアミド、N-メチルピロリジン-2-オン、ジメチルスルホキシドなどを単一又は混合して用いることができる。反応温度は0から200℃であり、好ましくは30から100℃である。反応時間は0.1から100時間であり、好ましくは0.5から24時間である。
本工程は化合物(I-5)からチオイソシアネート(I-6)を用いて化合物(I-7)を得る反応である。チオイソシアネート(I-6)は、例えば国際公開2005-082855号公報に準じて、酸ハライド又はカルボン酸から別途調製することができる。化合物(I-5)に対しこれら化合物(I-6)は1から100当量用いることができ、好ましくは1.1から30当量である。本反応に用いる溶媒としては特に制限はなく、ヘキサン、トルエン、テトラヒドロフラン、アセトニトリル、N,N-ジメチルホルムアミド、N-メチルピロリジン-2-オン、メタノール、エタノール、イソプロパノールなどを単一又は混合して用いることができる。反応温度は-30から200℃であり、好ましくは0から100℃である。反応時間は0.1から100時間であり、好ましくは0.5から24時間である。
本工程はエステル(I-7)からカルボン酸(I-8)を得る反応である。塩基性条件下、酸性条件下、あるいは接触水素添加反応などを用いてエステルからカルボン酸へと導くことが出来る。
また、それぞれの反応温度は-30から200℃であり、好ましくは0から100℃である。それぞれの反応時間は0.1から100時間であり、好ましくは0.5から24時間である。
本工程はカルボン酸(I-8)とアミン(I-9)の縮合反応である。本工程ではカルボン酸(I-8)から酸ハライドを経由して化合物(I)を得る方法と、一般的に用いられている縮合剤を用いて化合物(I)を得る方法がある。
このようにして得られた酸ハライドにアミン(I-9)を導入して化合物(I)を得ることができる。必要に応じて塩基を用いてもよく、塩基としては、トリメチルアミン、トリエチルアミン、トリプロピルアミン、ジイソプロピルエチルアミン、N-メチルモルホリン、ピリジン、4-(N,N-ジメチルアミノ)ピリジン、ルチジン、コリジンなどの有機アミン類や炭酸水素ナトリウム、炭酸ナトリウム、炭酸カリウム、炭酸セシウム、ナトリウムメトキシド、カリウムメトキシド、ナトリウムエトキシド、カリウムエトキシド、カリウムtert-ブトキシドなどの無機塩類が挙げられる。アミン(I-9)は1から100当量用いることができ、好ましくは1.1から50当量である。また、溶媒としてテトラヒドロフラン、1,4-ジオキサン、トルエン、塩化メチレン、クロロホルム、アセトニトリル、N,N-ジメチルホルムアミド、N、N-ジメチルアセトアミド、ジメチルスルホキシドなどが用いられる。
結合剤としては、水、エタノール、1-プロパノール、2-プロパノール、単シロップ、ブドウ糖液、α-デンプン液、ゼラチン液、D-マンニトール、カルボキシメチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルスターチ、メチルセルロース、エチルセルロース、シェラック、リン酸カルシウム、ポリビニルピロリドン等が挙げられる。
滑沢剤としては、精製タルク、ステアリン酸塩ナトリウム、ステアリン酸マグネシウム、ホウ砂、ポリエチレングリコール等が挙げられる。
着色剤としては、酸化チタン、酸化鉄等が挙げられる。
矯味・矯臭剤としては白糖、橙皮、クエン酸、酒石酸等が挙げられる。
経口用液体製剤を調製する場合は、本発明化合物に矯味剤、緩衝剤、安定化剤、矯臭剤等を加えて常法により内服液剤、シロップ剤、エリキシル剤等を製造することができる。この場合矯味・矯臭剤としては、前記に挙げられたものでよく、緩衝剤としては、クエン酸ナトリウム等が、安定剤としては、トラガント、アラビアゴム、ゼラチン等が挙げられる。必要により、腸溶性コーティング又は、効果の持続を目的として、経口製剤に公知の方法により、コーティングを施すこともできる。このようなコーティング剤にはヒドロキシプロピルメチルセルロース、エチルセルロース、ヒドロキシメチルセルロース、ヒドロキシプロピルセルロース、ポリオキシエチレングリコール、Tween80(登録商標)等が挙げられる。
坐剤を調製する場合は、本発明化合物に当業界において公知の製剤用担体、例えば、ポリエチレングリコール、ラノリン、カカオ脂、脂肪酸トリグリセリド等を、さらに必要に応じてTween80(登録商標)のような界面活性剤等を加えた後、常法により製造することができる。
貼付剤を調製する場合は、通常の支持体に前記軟膏、クリーム、ゲル、ペースト等を常法により塗布すればよい。支持体としては、綿、スフ、化学繊維からなる織布、不織布や軟質塩化ビニル、ポリエチレン、ポリウレタン等のフィルム或いは発泡体シートが適当である。
tert-ブチル 4-クロロ-7-メトキシキノリン-6-カルボキシレート(1a)
1H-NMR(CDCl3)δ:8.73(1H,d,J=4.2Hz),8.50(1H,s),7.49(1H,s),7.38(1H,d,J=4.8Hz),4.03(3H,s),1.64(9H,s);ESI-MS m/z294(MH+).
1H-NMR(DMSO-d6)δ:8.75(1H,d,J=4.8Hz),8.47(1H,dd,J=10.4Hz,2.8Hz),8.38(1H,s),8.23(1H,ddd,J=8.8Hz,1.2Hz,1.2Hz),7.74(1H,t,J=8.0Hz),7.55(1H,s),6.78(1H,d,J=5.2Hz),3.99(3H,s),1.54(9H,s);ESI-MS m/z415(MH+).
1H-NMR(DMSO-d6)δ:8.65(1H,d,J=5.2Hz),8.40(1H,s),7.48(1H,s),7.10(1H,t,J=9.2Hz),6.55(1H,dd,J=13.2Hz,2.8Hz),6.48-6.44(2H,m),5.51(2H,s),3.96(3H,s),1.55(9H,s);ESI-MS m/z385(MH+).
1H-NMR(CDCl3)δ:12.62(1H,s),8.70(1H,s),8.58(1H,s),8.09(1H,dd,J=11.8Hz,2.0Hz),7.81(1H,s),7.51-7.30(7H,m),6.71(1H,s),4.18(3H,s),3.78(2H,s),1.64(6H,s);ESI-MS m/z562(MH+).
1H-NMR(DMSO-d6)δ:12.54(1H,s),11.86(1H,s),8.98(1H,d,J=6.4Hz),8.70(1H.s),8.11(1H,d,J=12.4Hz),7.74.-7.73(1H,m),7.65-7.60(2H,m),7.37-7.32(4H,m),7.30-7.25(1H,m),6.91(1H,d,J=6.0Hz),4.04(3H,s),3.83(2H,s);ESI-MS m/z506(MH+).
1H-NMR(DMSO-d6)δ:12.51(1H,s),11.83(1H,s),8.69(1H,d,J=5.6Hz)8.54(1H.s),8.39(1H,t,J=4.8Hz),8.04(1H,dd,J=12.4Hz,J=2.0Hz),7.58-7.49(3H,m),7.39-7.34(4H,m),7.32-7.27(1H,m),6.53(1H,d,J=5.2Hz),4.02(3H,s),3.84(2H,s),3.58-3.50(1H,m),3.45(2H,t,J=6.0Hz),3.40-3.36(2H,m),1.79-1.68(2H,m),1.09(6H,d,J=6.0Hz);ESI-MS m/z605(MH+).
N-((2,2-ジメチル-1,3-ジオキソラン-4-イル)メチル)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシキノリン-6-カルボキサミド(2)
1H-NMR(CDCl3)δ:12.50(1H,s),9.26(1H,s),8.66(1H,dd,J=5.4Hz,0.8Hz),8.52(1H,s),8.23(1H,t,J=5.6Hz),7.96(1H,dd,J=11.2Hz,J=2.8Hz),7.53(1H,s),7.46-7.37(4H,m),7.32-7.28(3H,m),6.44(1H,dd,J=7.2Hz),4.43-4.38(1H,m),4.13-4.09(1H,m),4.12(3H,s),3.79-3.71(3H,m),2.42(2H,t,J=8.0Hz),3.76(2H,s),1.49(3H,s),1.43(1H,s),1.39(2H,s);ESI-MS m/z619(MH+).
N-(2,3-ジヒドロキシプロピル)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシキノリン-6-カルボキサミド(3)
1H-NMR(DMSO-d6)δ:12.50(1H,s),11.82(1H,s),8.69(1H,s),8.69(1H,d,J=5.2Hz),8.48(1H.t,J=5.6Hz),8.39(1H,t,J=4.8Hz),8.04(1H,dd,J=12.0Hz,J=2.4Hz),7.58-7.50(3H,m),7.37-7.33(4H,m),7.31-7.26(1H,m),6.52(1H,d,J=5.4Hz),4.92(1H,br),4.65(1H,br),4.03(3H,s),3.82(2H,s),3.65(1H,t,J=5.6Hz),3.52-3.46(1H,m),3.43-3.37(3H,m,J=6.0Hz);ESI-MS m/z579(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(ピリジン-3-イルメチル)キノリン-6-カルボキサミド(4)
1H-NMR(DMSO-d6)δ:12.50(1H,s),11.81(1H,s),9.01(1H,t,J=7.6Hz),8.69(1H,d,J=5.2Hz),8.58(1H,d,J=1.6Hz),8.57(1H,s),8.45(1H,dd,J=4.8Hz,1.0Hz),8.02(1H,dd,J=12.8Hz,1.6Hz),7.77(1H,d,J=8.0Hz),7.56-7.48(4H,m),7.39-7.33(6H,m),7.31-7.26(1H,m),6.52(1H,d,J=5.6Hz),4.55(2H,d,J=6.0Hz),4.03(3H,s),3.82(2H,s),;ESI-MS m/z596(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(3-(2-オキソピロリジン-1-イル)プロピル)キノリン-6-カルボキサミド(5)
1H-NMR(CDCl3)δ:12.53(1H,s),9.24(1H,s),8.76(1H,s),8.65(1H,d,J=5.6Hz),8.53(1H,t,J=6.0Hz),7.95(1H,dd,J=12.0Hz,J=2.4Hz),7.52(1H,s),7.45-7.37(4H,m),7.32-7.30(2H,m),7.23(1H,d,J=8.4Hz),6.42(1H,dd,J=5.2Hz,1.2Hz),4.17(3H,s),3.76(2H,s),3.52-3.42(6H,m),2.42(2H,t,J=8.0Hz),2.06(2H,tt,J=7.6Hz),1.86(2H,tt,J=6.0Hz),;ESI-LRMS m/z630(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-メチルキノリン-6-カルボキサミド(6)
1H-NMR(DMSO-d6)δ:12.51(1H,s),11.83(1H,s),8.69(1H,d,J=4.8Hz),8.60(1H,s),8.38(1H,d,J=4.8Hz),8.03(1H,dd,J=12.4Hz,J=2.0Hz),7.58-7.50(4H,m),7.39-7.34(4H,m),6.53(1H,d,J=5.2Hz),4.03(3H,s),3.84(2H,s),2.84(3H,d,J=4.8Hz),;ESI-MS m/z518(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(メトキシエチル)キノリン-6-カルボキサミド(7)
1H-NMR(DMSO-d6)δ:12.51(1H,s),11.83(1H,s),8.71-8.69(1H,m),8.62(1H,s),8.54-8.44(1H,m),8.04(1H,dd,J=12.4Hz,1.6Hz),7.58-7.50(3H,m),7.36-7.34(4H,m),7.32-7.27(1H,m),6.53(1H,d,J=4.8Hz),4.04(3H,s),3.84(2H,s),3.50-3.48(4H,m),3.30(3H,s);ESI-MS m/z562(MH+).
N-(2-(ジエチルアミノ)エチル)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシキノリン-6-カルボキサミド(8)
1H-NMR(DMSO-d6)δ:12.50(1H,s),11.83(1H,s),8.73-8.70(1H,m),8.72(1H,s),8.51(1H,t,J=5.2Hz),8.04(1H,dd,J=12.8Hz,1.6Hz),7.58-7.50(3H,m),7.38-7.33(4H,m),7.31-7.27(1H,m),6.53(1H,d,J=6.0Hz),4.05(3H,s),3.84(2H,s),3.42-3.37(2H,m),2.67-2.53(6H,m),1.01(6H,t,J=7.2Hz);ESI-MS m/z604(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(2-モルホリノエチル)キノリン-6-カルボキサミド(9)
1H-NMR(CDCl3)δ:12.53(1H,s),9.26(1H,s),9.08(1H,t,J=3.6Hz),8.72(1H,s),8.66(1H,d,J=5.0Hz),7.95(1H,dd,J=11.6Hz,2.4Hz),7.55(1H,s),7.45-7.36(4H,m),7.32-7.24(3H,m),6.44(1H,dd,J=5.2Hz,0.8Hz),4.37(2H,d,J=4.0Hz),4.18(3H,s),3.79-3.72(7H,m),3.77(2H,s),3.52(2H,t,J=4.8Hz);ESI-MS m/z618(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-N-(2-(2-ヒドロキシエトキシ)エチル)-7-メトキシキノリン-6-カルボキサミド(10)
1H-NMR(DMSO-d6)δ:12.51(1H,s),11.83(1H,s),8.70(1H,d,J=5.2Hz),8.64(1H,s),8.49(1H,t,J=5.2Hz),8.04(1H,d,J=12.2Hz),7.58-7.50(3H,m),7.38-7.34(4H,m),7.31-7.27(1H,m),6.52(1H,d,J=5.2Hz),4.62(1H,t,J=5.2Hz),4.04(3H,s),3.84(2H,s),3.58(2H,t,J=5.6Hz),3.54-3.47(6H,m);ESI-MS m/z592(MH+).
N-(2-アセタミドエチル)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシキノリン-6-カルボキサミド(11)
1H-NMR(DMSO-d6)δ:12.49(1H,s),11.82(1H,s),8.68(1H,dd,J=5.2Hz,2.8Hz),8.63(1H,d,J=2.4Hz),8.48(1H,t,J=5.6Hz),8.02(1H,d,J=12.4Hz),7.98(1H,s),7.56-7.49(3H,m),7.36-7.32(4H,m),7.30-7.26(1H,m),6.51(1H,d,J=5.2Hz),4.02(3H,s),3.82(2H,s),3.38-3.35(2H,m),3.28-3.22(2H,s),1.82(3H,s);ESI-MS m/z590(MH+).
N-(1,3-ジヒドロキシプロパン-2-イル)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシキノリン-6-カルボキサミド(12)
1H-NMR(DMSO-d6)δ:12.50(1H,s),11.82(1H,s),8.74(1H,s),8.69(1H,d,J=5.2Hz),8.29(1H,d,J=8.0Hz),8.03(1H,dd,J=12.0Hz,2.0Hz),7.57-7.50(3H,m),7.35-7.33(4H,m),7.31-7.26(1H,m),6.52(1H,d,J=5.2Hz),4.80(2H,t,J=5.2Hz),4.04(3H,s),3.99-3.94(1H,m),3.83(2H,s),3.61-3.56(2H,m),3.54-3.47(2H,m);ESI-MS m/z579(MH+).
tert-ブチル 4-(4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシキノリン-6-カルボキサミド)-6-カルボキサミド)ピペリジン-1-カルボキシレート(13)
1H-NMR(CDCl3)δ:12.50(1H,s),9.24(1H,s),8.66(1H,d,J=5.4Hz),8.49(1H,s),7.96(1H,dd,J=11.6Hz,2.4Hz),7.83(1H,d,J=7.6Hz),7.53(1H,s),7.47-7.37(4H,m),7.33-7.29(3H,m),6.44(1H,d,J=5.0Hz,1.2Hz),4.23(1H,br),4.11(3H,s),4.03-4.01(1H,m),3.76(2H,s),3.04(3H,t,J=12.0Hz),2.92(1H,t,J=10.8Hz),2.09-1.98(3H,m),1.48(9H,s);ESI-MS m/z688(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(ピペリジン-4-イル)キノリン-6-カルボキサミド・2塩酸塩(14)
1H-NMR(DMSO-d6)δ:12.50(1H,s),11.82(1H,s),8.67(1H,d,J=5.2Hz),8.44(1H,s),8.30(1H,d,J=7.6Hz),8.02(1H,dd,J=12.8Hz,1.6Hz),7.57-7.44(3H,m),7.37-7.33(4H,m),7.31-7.26(1H,m),6.51(1H,d,J=5.2Hz),4.04-3.96(1H,br),3.99(3H,s),3.93(2H,s),3.96-3.79(4H,m),3.83(2H,s),2.92(2H,br),1.83(1H,m);ESI-MS m/z588(MH+).
N-(1-(エチルカルバモイル)ピペリジン-4-イル)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシキノリン-6-カルボキサミド(15)
1H-NMR(DMSO-d6)δ:12.50(1H,s),11.82(1H,s),8.67(1H,d,J=5.6Hz),8.44(1H,s),8.28(1H,d,J=8.0Hz),8.02(1H,d,J=12.8),7.56-7.48(3H,m),7.35-7.28(5H,m),6.51(1H,d,J=4.8Hz),6.45(1H,t,J=4.8Hz),3.99(4H,s),3.88(2H,d,J=12.8Hz),3.82(2H,s),3.06-2.99(2H,m),2.82(3H,t,J=12.0Hz),1.43-1.34(3H,m),0.99(3H,t,J=7.2Hz);ESI-MS m/z659(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(2-オキソアゼパン-3-イル)キノリン-6-カルボキサミド(16)
1H-NMR(DMSO-d6)δ:12.50(1H,s),11.82(1H,s),9.19(1H,d,J=6.0Hz),8.90(1H,s),8.71(1H,d,J=5.2Hz),8.05-7.96(2H,m),7.60-7.51(3H,m),7.37-7.33(4H,m),7.31-7.26(1H,m),6.53(1H,d,J=4.4Hz),4.65-4.61(1H,m),4.10(3H,s),3.96(2H,s),3.83(2H,s),2.07(1H,d,J=12.8Hz),1.94-1.90(1H,m),1.79-1.69(2H,m),1.47-1.38(1H,m),1.29-1.20(1H,m);ESI-MS m/z616(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(2-オキソ-2-(ピロリジン-1-イル)エチル)キノリン-6-カルボキサミド(17)
1H-NMR(DMSO-d6)δ:12.50(1H,s),11.82(1H,s),8.83(2H,d,J=1.2Hz),8.71(1H,dd,J=5.2Hz,1.6Hz),8.05-7.99(1H,m),7.60-7.53(3H,m),7.35-7.33(4H,m),7.30-7.28(1H,m),6.53(1H,d,J=5.2Hz),4.14(2H,d,J=4.0Hz),4.08(3H,d,J=1.2Hz),3.83(2H,s),3.48-3.44(2H,m),3.39-3.24(2H,m),1.94-1.88(2H,m),1.83-1.76(2H,m);ESI-MS m/z616(MH+).
N-(1-アセチルピペリジン-4-イル)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシキノリン-6-カルボキサミド(18)
1H-NMR(DMSO-d6)δ:12.50(1H,s),11.82(1H,s),8.67(2H,d,J=5.2Hz),8.45(1H,s),8.02(1H,dd,J=12.4Hz,2.4Hz),7.56-7.49(3H,m),7.37-7.33(4H,m),7.31-7.26(1H,m),6.52(1H,d,J=5.2Hz),4.23(1H,d,J=13.2Hz),4.10-3.98(1H,br),4.00(3H,s),3.83(2H,s),3.78(1H,d,J=14.4Hz),3.21-3.15(2H,m),2.78(1H,t,J=10.8Hz),2.68-2.65(1H,m),2.00(3H,s),1.93-1.88(1H,m),1.86-1.81(1H,m),;ESI-MS m/z630(MH+).
tert-ブチル 4-(2-フルオロ-4-(3-(2-(4-フルオロフェニル)アセチル)チオウレイド)フェノキシ)-7-メトキシキノリン-6-カルボキシレート(19a)
1H-NMR(CDCl3)δ:12.47(1H,s),11.82(1H,s),8.73(1H,s),8.65(1H,d,J=4.4Hz),7.95(1H,dd,J=11.2Hz,2.8Hz),7.49(1H,s),7.43-7.40(1H,m),7.31-7.25(3H,m),7.15(2H,m),6.42(1H,dd,J=5.2Hz,1.2Hz),4.03(3H,s),3.74(2H,s),1.64(9H,s);ESI-MS m/z580(MH+).
1H-NMR(DMSO-d6)δ:12.52(1H,s),11.85(1H,s),8.94(1H,d,J=6.0Hz),8.68(1H,s),8.11(1H,d,J=12.4Hz),7.66(1H,s),7.62(1H,d,J=3.4Hz),7.39(2H,dd,J=8.4Hz,5.6Hz),7.19(2H,t,J=8.8Hz),6.85(1H,d,J=6.0Hz),4.04(3H,s),3.84(2H,s);ESI-MS m/z524(MH+).
1H-NMR(DMSO-d6)δ:12.47(1H,s),11.81(1H,s),9.20(1H,d,J=5.6Hz),8.90(1H,s),8.71(1H,d,J=5.2Hz),8.04-7.96(2H,m),7.60(1H,s),7.57-7.51(2H,m),7.39-7.36(2H,m),7.20-7.15(2H,m),6.53(1H,d,J=5.2Hz),4.65-4.61(1H,m),4.10(3H,s),3.83(2H,s),3.48-3.44(2H,m),2.08-2.05(1H,m),1.94-1.90(1H,m),1.79-1.72(2H,m),1.44-1.40(1H,m),1.29-1.19(1H,m)
(S)-tert-ブチル 2-(3-フルオロピロリジン-1-イル)-2-オキソエチルカルバメイト(20a)
1H-NMR(CDCl3)δ:5.45(1H,br),5.40-5.19(1H,m),4.00-3.82(3H,m),3.72-3.49(3H,m),4.10(3H,s),3.83(2H,s),3.48-3.44(2H,m),2.41-2.24(1H,m),2.19-1.91(1H,m);FAB-MS m/z247(MH+).
1H-NMR(DMSO-d6)δ:8.28(3H,br),5.48-5.22(1H,m),3.88-3.27(6H,m),2.29-1.89(2H,m)
1H-NMR(DMSO-d6)δ:12.50(1H,s),11.82(1H,s),8.83(1H,t,J=4.4Hz),8.81(1H,s),8.71(1H,d,J=5.2Hz),7.59(1H,s),7.57-7.51(2H,m),7.37-7.33(5H,m),7.31-7.25(1H,m),6.53(1H,d,J=5.6Hz),5.49-27(1H,m),4.27-4.13(2H,m),4.08(3H,s),3.82(2H,s),3.86-3.63(3H,m),2.32-2.05(3H,m);ESI-MS m/z634(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(2-モルホリノ-2-オキソエチル)キノリン-6-カルボキサミド(21)
1H-NMR(DMSO-d6)δ:12.50(1H,s),11.82(1H,s),8.85-8.83(1H,m),8.82(1H,s),8.71(1H,dd,J=5.2Hz),8.03(1H,d,J=12.0Hz),7.60(1H,s),7.55(1H,s),7.55-7.50(1H,m),7.35-7.28(5H,m),6.52(1H,d,J=5.2Hz),4.24(2H,d,J=4.8Hz),4.08(2H,s),3.96(3H,s),3.82(2H,s),3.59(2H,d,J=13.2Hz),3.53-3.48(2H,m),3.15-3.00(2H,m);ESI-MS m/z632(MH+).
N-(2-(ジメチルアミノ)-2-オキソエチル)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシキノリン-6-カルボキサミド(22)
1H-NMR(DMSO-d6)δ:12.51(1H,s),11.82(1H,s),8.87-8.84(2H,m),8.72(1H,dd,J=5.4Hz,0.6Hz),7.60-7.52(3H,m),7.38-7.33(4H,m),7.31-7.26(1H,m),6.54(1H,d,J=4.8Hz),4.21(2H,d,J=4.8Hz),4.09(3H,s),3.83(2H,s),3.00(3H,s),2.89(3H,m);ESI-MS m/z590(MH+).
4-(2-フルオロ-4-(3-(2-(4-フルオロフェニル)アセチル)チオウレイド)フェノキシ)-N-(2-ヒドロキシブチル)-7-メトキシキノリン-6-カルボキサミド(23)
1H-NMR(DMSO-d6)δ:12.47(1H,s),11.81(1H,s),8.69(1H,d,J=4.0Hz),8.65(1H,s),8.39(1H,t,J=8.8Hz),8.02(1H,d,J=11.2Hz),7.55-7.49(3H,m),7.37(2H,dd,J=7.0Hz,6.0Hz),7.17(2H,t,J=8.8Hz),6.52(1H,d,J=5.4Hz),4.80(1H,d,J=4.8Hz),4.03(3H,s),3.86(2H,s),3.82(2H,s),1.51-1.45(2H,m),1.39-1.31(2H,m),0.90(3H,t,J=7.2Hz);ESI-MS m/z595(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-N-(2-ヒドロキシ-2-メチルプロピル)-7-メトキシキノリン-6-カルボキサミド(24)
1H-NMR(DMSO-d6)δ:12.50(1H,s),11.80(1H,s),8.69(1H,d,J=5.6Hz),8.66(1H,s),8.34(1H,t,J=6.0Hz),8.02(1H,d,J=11.2Hz),7.57-7.52(3H,m),7.37-7.33(4H,m),7.30-7.27(1H,m),6.52(1H,d,J=5.6Hz),4.63(1H,s),4.04(3H,s),3.83(2H,s),3.81(1H,d,J=2.4Hz),1.55(1H,s),1.14(6H,s);ESI-MS m/z577(MH+)
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-N-((1-ヒドロキシシクロヘキシル)メチル)-7-メトキシキノリン-6-カルボキサミド(25)
1H-NMR(CDCl3)δ:12.51(1H,s),9.25(1H,s),8.66(1H,d,J=5.2Hz),8.55(1H,s),8.23(1H,t,J=5.4Hz),7.96(1H,dd,J=11.6Hz,2.4Hz),7.53(1H,s),7.46-7.37(4H,m),7.33-7.23(3H,m),6.44(1H,dd,J=5.2Hz,0.8Hz),4.12(3H,s),3.76(2H,s),3.58(1H,d,J=5.8Hz),1.65-1.52(10H,m),1.37(1H,br);ESI-MS m/z617(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-N-((4-ヒドロキシテトラヒドロ-2H-ピラン-4-イル)メチル)-7-メトキシキノリン-6-カルボキサミド(26)
1H-NMR(CDCl3)δ:12.51(1H,s),9.26(1H,s),8.67(1H,d,J=5.4Hz),8.45(1H,s),8.26(1H,t,J=6.0Hz),7.96(1H,d,J=11.6Hz,2.4Hz),7.55(1H,s),7.47-7.38(4H,m),7.33-7.24(3H,m),6.52(1H,dd,J=5.2Hz,0.8Hz),4.13(3H,s),3.83-3.78(4H,m),3.76(2H,s),3.61(2H,d,J=6.4Hz),3.30(1H,br),1.78(2H,m),1.64(2H,d,J=12.8Hz);ESI-MS m/z619(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(2-(メチルスルホニル)エチル)キノリン-6-カルボキサミド(27)
1H-NMR(DMSO-d6)δ:12.50(1H,s),11.83(1H,s),8.77(1H,t,J=5.6Hz),8.70-8.69(2H,m),8.03(1H,dd,J=12.2Hz,1.8Hz),7.57-7.50(4H,m),7.38-7.34(4H,m),7.31-7.26(1H,m),6.53(1H,d,J=5.6Hz),4.03(3H,s),3.83(2H,s),3.76(2H,dt,J=6.2Hz),3.42(2H,d,J=6.8Hz),3.07(3H,s),;ESI-MS m/z611(MH+).
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-o-トリルキノリン-6-カルボキサミド(28)
化合物1の合成と同様に、化合物1e(32mg)とオルトトルイジン(7.59μL)、DMTMM・n水和物(19.6mg)より、表記化合物28(19.8mg、収率56%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.51(1H,s),11.82(1H,s),9.96(1H,s),8.76(1H,s),8.72(2H,d,J=5.2Hz),7.64(1H,s),7.81(1H,d,J=7.2Hz),7.58-7.52(2H,m),7.36-7.33(4H,m),7.30-7.21(3H,m),7.12(1H,t,J=7.6Hz),6.55(1H,d,J=5.6Hz),4.12(3H,s),3.83(2H,s),2.34(3H,s);ESI-MS m/z595(MH+)
(S)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-N-(2-ヒドロキシ-1-フェニルエチル)-7-メトキシキノリン-6-カルボキサミド(29)
化合物1の合成と同様に、化合物1e(44mg)と(S)-2-アミノ-2-フェニルエタノール(15.5mg)、DMTMM・n水和物(19.1mg)より、表記化合物29(47.0mg、収率86%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.50(1H,s),11.82(1H,s),8.83(1H,d,J=8.0Hz),8.69(1H,d,J=5.2Hz),8.58(1H,s),8.02(1H,dd,J=11.6Hz,1.6Hz),7.57(1H,s),7.57-7.49(2H,m),7.41-7.31(7H,m),7.29-7.22(3H,m),6.52(1H,d,J=5.2Hz),5.09(1H,q,J=7.6Hz),5.02(1H,t,J=5.6Hz),4.06(3H,s),3.82(2H,s),3.70-3.67(2H,m);ESI-MS m/z625(MH+)
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-N-(2-ヒドロキシ-2-(2-メチル-2H-テトラゾール-5-イル)エチル)-7-メトキシキノリン-6-カルボキサミド(30)
化合物1の合成と同様に、化合物1e(30.0mg)と2-アミノ-1-(2-メチル-2H-テトラゾール-5-イル)エタノール(12.7mg)、DMTMM・n水和物(19.7mg)より、表記化合物30(31.2mg、収率83%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.50(1H,s),11.82(1H,s),8.68(1H,d,J=5.2Hz),8.64(1H,s),8.58-8.53(1H,m),8.03(1H,d,J=11.6Hz),7.57-7.52(3H,m),7.36-7.33(4H,m),7.30-7.26(1H,m),6.52(1H,d,J=5.6Hz),6.07(1H,d,J=6.4Hz),4.34(3H,s),4.00(3H,s),3.83-3.82(3H,m),3.78-3.70(2H,m);ESI-MS m/z649(MH+)
(S)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-N-(1-ヒドロキシブタン-2-イル)-7-メトキシキノリン-6-カルボキサミド(31)
化合物1の合成と同様に、化合物1e(81.7mg)と(S)-2-アミノブタン-1-オール(22.8μL)、DMTMM・n水和物(53.7mg)より、表記化合物31(89.6mg、収率96%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.50(1H,s),11.82(1H,s),8.68(1H,d,J=5.1Hz),8.55(1H,s),8.12(1H,d,J=8.6Hz),8.02(1H,dd,J=12.0Hz,1.4Hz),7.58-7.48(3H,m),7.36-7.25(4H,m),7.31-7.25(1H,m),6.51(1H,d,J=5.4Hz),4.75(1H,t,J=5.6Hz),4.01(3H,s),3.92-3.85(1H,m),3.82(2H,s),3.52-3.47(1H, m),3.45-3.38(1H,m),1.78-1.70(1H,m),1.50-1.40(1H,m),0.92(3H,t,J=7.6Hz);ESI-MS m/z577(MH+)
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-N-(1-ヒドロキシテトラヒドロチオフェン-3-イル)-7-メトキシキノリン-6-カルボキサミド(32)
化合物1の合成と同様に、化合物1e(25.7mg)と4-アミノテトラヒドロチオフェン-3-オール塩酸塩(16.9mg)、DMTMM・n水和物(11.5mg)、トリエチルアミン(14.2μL)より、表記化合物32(30.2mg、収率93%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.50(1H,s),11.82(1H,s),8.81(1H,s),8.71(1H,d,J=5.2Hz),8.57(1H,d,J=7.2Hz),8.03(1H,dd,J=13.2Hz,2.4Hz),7.58(1H,s),7.57-7.50(2H,m),7.36-7.25(5H,m),6.54(1H,dd,J=5.2Hz,0.8Hz),4.37(2H,d,J=4.8Hz),4.06(3H,s),3.83(2H,s),3.10(1H,dd,J=12.0Hz,4.4Hz),3.02(1H,dd,J=9.6Hz,7.2Hz),2.80-2.62(3H,m);ESI-MS m/z625(MH+)
tert-ブチル 2-(4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシキノリン-6-カルボキサミド)アセテート(33a)
化合物1の合成と同様に、化合物1e(65.2mg)とグリシンtert-ブチルエステル塩酸塩(18.9mg)、DMTMM・n水和物(39.9mg)、トリエチルアミン(42.1μL)より、化合物33a(67.2mg、収率90%)を得た。
1H-NMR(400Hz,CDCl3)δ:12.51(1H,s),9.28(1H,d,J=4.8Hz),8.66(1H,d,J=5.6Hz),8.59(1H,br),8.51(1H,dd,J=4.8Hz),7.95(1H,dd,J=12.0Hz,2.4Hz),7.46-7.36(5H,m),7.32-7.23(3H,m),6.44(1H,d,J=4.8Hz,1.2Hz),4.24(2H,d,J=4.8Hz),4.16(3H,s),3.76(2H,s),1.53(9H,s);ESI-MS m/z619(MH+)
化合物1eの合成と同様に、化合物33a(55.7mg)より、化合物33b(37.2mg、収率63%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.55(1H,s),11.86(1H,s),8.98(1H,d,J=6.0Hz),8.87(1H,dd,J=5.6Hz),8.76(1H,s),8.12(1H,dd,J=12.4Hz,1.2Hz),7.74(1H,s),7.64-7.62(2H,m),7.36-7.34(5H,m),7.32-7.27(1H,m),6.91(1H,d,J=6.4Hz),4.09(3H,s),4.01(2H, d, J=5.6Hz),3.83(2H,s);ESI-MS m/z563(MH+)
化合物1の合成と同様に、化合物33b(50mg)、2-メトキシエタンアミン(11μL)、DMTMM・n水和物(34.6mg)、N-メチルモルホリン(18.4μL)より、表記化合物33(12.0mg、収率23%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.51(1H,s),11.83(1H,s),8.76(1H,s),8.75(1H,t,J=5.4Hz),8.71(1H,d,J=5.4Hz),8.06-8.00(2H,m),7.59(1H,s),7.57-7.50(2H,m),7.38-7.26(5H,m),6.53(1H,d,J=5.4Hz),4.07(3H,s),3.97(2H,d,J=5.4Hz),3.84(2H,s),3.39-3.35(2H,m),3.30-3.27(2H,m),3.25(3H,s);ESI-MS m/z620(MH+)
(S)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-N-(2-(2-(ヒドロキシメチル)ピロリジン-1-イル)-2-オキソエチル)-7-メトキシキノリン-6-カルボキサミド(34)
化合物1の合成と同様に、化合物33b(50mg)、(S)-ピロリジン-2-イルメタノール(11μL)、DMTMM・n水和物(30mg)、N-メチルモルホリン(24μL)より、表記化合物34(32mg、収率60%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.51(1H,brs),11.83(1H,brs),8.88-8.83(2H,m),8.72(1H,d,J=5.1Hz),8.04(1H,d,J=12.2Hz),7.63-7.51(3H,m),7.39-7.26(5H,m),6.54(1H,d,J=5.1Hz),4.74(1H,t,J=5.5Hz),4.39-4.22(1H,m),4.18-4.13(1H,m),4.10(3H,s),4.05-3.95(1H,m),3.84(2H,s),3.56-3.41(3H,m),2.02-1.76(5H,m);ESI-MS m/z646(MH+)
N-(2-(エチル(2-ヒドロキシ-2-メチルプロピル)アミノ)-2-オキソエチル)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシキノリン-6-カルボキサミド(35)
化合物1の合成と同様に、化合物33b(35.0mg)、1-(エチルアミノ)-2-メチルプロパン-2-オール(17.1mg)、DMTMM・n水和物(19.4mg)より、表記化合物35(12.3mg、収率32%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.50(1H,s),11.82(1H,s),8.86(1H,sbr),8.84(1H,d,J=2.7Hz),8.71(1H,d,J=5.4Hz),8.03(1H,dd,J=11.7Hz,2.0Hz),7.59(1H,s),7.57-7.52(2H,m),7.37-7.32(4H,m),7.21-7.25(1H,m),6.53(1H,d,J=5.6Hz),4.32-4.27(2H,m),4.09,4.07(3H,s),3.82(2H,s),3.50-3.20(4H,m),1.18-1.13(5H,m),1.09-1.01(5H,m);ESI-MS m/z662(MH+)
tert-ブチル 2-(4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシキノリン-6-カルボキサミド)プロパノエート(36a)
化合物1の合成と同様に、化合物1e(100mg)とアラニンtertブチルエステル塩酸塩(47mg)、DMTMM・n水和物(71mg)より、化合物36a(109mg、収率87%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.57(1H,s),11.89(1H,s),8.76(1H,d,J=5.2Hz),8.65(1H,s),8.61(1H,t,J=5.2Hz),8.10(1H,d,J=12.4Hz),7.60-7.30(8H,m),6.60(1H,d,J=5.2Hz),4.08(3H,s),3.90(2H,s),3.57(2H,td,J=6.5Hz,J=6.5Hz),2.57(2H,t,J=6.5Hz),1.47(9H,s);ESI-MS m/z633(MH+)
化合物1eの合成と同様に、化合物36a(95mg)より、化合物36b(92mg、収率100%)を得た。
1H-NMR(400Hz,DMSO-d6)δ;12.55(1H,s),11.86(1H,s),8.94(1H,d,J=5.9Hz),8.68(1H,s),8.65(1H,t,J=5.9Hz),8.11(1H,d,J=12.4Hz),7.69-7.58(3H,m),7.38-7.25(5H,m),6.87(1H,d,J=5.9Hz),4.05(3H,s),3.84(2H,s),3.54(2H,td,J=6.7Hz,J=6.7Hz),2.55(2H,t,J=6.7Hz);ESI-MS m/z577(MH+)
実施例1の合成と同様に、化合物36b(30mg)とジメチルアミン塩酸塩(6.0mg)、DMTMM・n水和物(20mg)、N-メチルモルホリン(16μL)より、表記化合物36(21.2mg、収率68%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.51(1H,s),11.83(1H,s),8.72(1H,s),8.70(1H,d,J=5.2Hz),8.66(1H,t,J=5.9Hz),8.04(1H,d,J=12.2Hz),7.58-7.25(8H,m),6.53(1H,d,J=5.2Hz),4.04(3H,s),3.84(2H,s),3.54(2H,td,J=6.4Hz,J=6.4Hz),2.97(3H,s),2.85(3H,s),2.61(2H,t,J=6.4Hz);ESI-MS m/z604(MH+)
4-(2-フルオロ-4-(3-(2-(4-フルオロフェニル)アセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(2-モルホリノエチル)キノリン-6-カルボキサミド(37)
実施例1の合成と同様に、化合物19b(523mg)と2-モルホリノエタンアミン(171mg)、DMTMM・n水和物(360mg)より、表記化合物37(462mg、収率73%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.47(1H,s),11.82(1H,s),8.70(1H,d,J=5.2Hz),8.70(1H,s),8.53-8.48(1H,m),8.02(1H,d,J=13.0Hz),7.59-7.48(3H,m),7.43-7.33(2H,m),7.24-7.13(2H,m),6.53(1H,d,J=5.2Hz),4.07(3H,s),3.84(2H,s),3.63-3.59(4H,m),3.49-3.32(6H,m),2.50-2.40(2H,m);ESI-MS m/z636(MH+)
(S)-4-(2-フルオロ-4-(3-(2-(4-フルオロフェニル)アセチル)チオウレイド)フェノキシ)-N-(1-ヒドロキシブタン-2-イル)-7-メトキシキノリン-6-カルボキサミド(38)
実施例1の合成と同様に、化合物19b(50mg)と(S)-2-アミノブタン-1-オール(12μL)、DMTMM・n水和物(34mg)より、表記化合物38(25mg、収率45%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.48(1H,sbr),11.82(1H,sbr),8.69(1H,d,J=5.2Hz),8.57(1H,s),8.13(1H,d,J=8.3Hz),8.03(1H,d,J=13.2Hz),7.58-7.50(3H,m),7.39(2H,dd,J=8.5Hz,J=5.6Hz),7.22-7.15(2H,m),6.52(1H,d,J=5.2Hz),4.77(1H,t,J=5.6Hz),4.03(3H,s),3.93-3.86(1H,m),3.84(2H,s),3.55-3.48(1H,m),3.45-3.40(1H,m),1.72-1.63(1H,m),1.53-1.42(1H,m),0.93(3H,t,J=7.4Hz);ESI-MS m/z595(MH+)
メチル 4-(2-フルオロ-4-ニトロフェノキシ)-7-メトキシキノリン-6-カルボキシレート(39a)
国際公開WO2005080377号公報に準じて合成したメチル 4-クロロ-7-メトキシキノリン-6-カルボキシレート(1.00g)、2-フルオロ-4-ニトロフェノール(936mg)、N,N-ジイソプロピルエチルアミン(1.35mL)より、化合物39a(1.38g、収率93%)を得た。
1H-NMR(CDCl3)δ:8.74(1H,s),8.73(1H,d,J=5.2Hz),7.54(1H,s),7.45-7.40(3H,m),6.49(1H,dd,J=5.0Hz,1.4Hz),4.06(3H,s),3.98(3H,s);ESI-MS m/z373(MH+).
化合物1bの合成と同様に、化合物39a(275mg)、鉄粉(206mg)、塩化アンモニウム(275mg)より、化合物39b(188mg、収率74%)を得た。
1H-NMR(400Hz,CDCl3)δ:8.83(1H,s),8.63(1H,d,J=5.2Hz),7.48(1H,s),7.03(1H,t,J=8.4Hz),6.56(1H,dd,J=11.6Hz,2.8Hz),6.50(1H,ddd,J=8.8Hz,2.6Hz,1.0Hz),6.41(1H,dd,J=5.0Hz,1.2Hz),4.04(3H,s),3.97(3H,s),3.84(2H,sbr);ESI-MS m/z343(MH+)
化合物39b(1.0g)をメタノール(10mL)に投入し、4M水酸化ナトリウム水溶液(650μL)と水(400μL)加えて室温にて2時間攪拌した。反応終了後、6N塩酸水溶液を加えてpHを3になるように調製し、析出した沈殿を濾取することにより、化合物39c(862mg、収率90%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:8.66(1H,d,J=5.4Hz),8.54(1H,s),7.48(1H,s),7.09(1H,dd,J=8.8Hz),6.55(1H,dd,J=13.0Hz,2.7Hz),6.48-6.43(2H,m),5.55(1H,sbr),3.96(3H,s);ESI-MS m/z329(MH+)
化合物1dの合成と同様に、化合物39c(1.79g)、2-フルオロフェニルアセチルチオイソシアネート(1.97g)とN,N-ジメチルアセトアミド(30mL)、トルエン(30mL)、エタノール(6mL)の混合溶媒を用いることにより、カルボン酸39d(1.89g、収率89%)の粗生成物を得た。それ以上精製せずに次の反応に用いた。
化合物1の合成と同様に、化合物39d(126mg)、DMTMM・n水和物(87mg)、1-アミノ-2-メチルプロパン-2-オール(37mg)より、表記化合物39(89mg、収率62%)を得た。
1H-NMR(400Hz,CDCl3)δ:12.43(1H,s),9.26(1H,s),8.67(1H,d,J=5.1Hz),8.59(1H,m),8.26(1H,m),7.97(1H,dd,J=11.5Hz,2.4Hz),7.54(1H,s),7.44-7.15(6H,m),6.44(1H,dd,J=5.4Hz,1.2Hz),4.13(3H,s),3.79(2H,s),3.57(2H,d,J=5.8Hz),2.57(1H,s),1.33 (6H,s);ESI-MS m/z595(MH+)
(S)-4-(2-フルオロ-4-(3-(2-(2-フルオロフェニル)アセチル)チオウレイド)フェノキシ)-N-(1-ヒドロキシブタン-2-イル)-7-メトキシキノリン-6-カルボキサミド(40)
化合物1の合成と同様に、化合物39d(121mg)、DMTMM・n水和物(83mg)、(S)-2-アミノブタン-1-オール(28mg)より、表記化合物40(84mg、収率61%)を得た。
1H-NMR(400Hz,CDCl3)δ:12.44(1H,s),9.25(1H,s),8.67(1H,d,J=5.1Hz),8.64(1H,s),8.03(1H,d,J=7.6Hz),7.97(1H,dd,J=11.6Hz,2.6Hz),7.54(1H,s),7.44-7.14(6H,m),6.45(1H,dd,J=5.1Hz,1.2Hz),4.12(3H,s),3.86(1H,m),3.79(2H,s),3.75(1H,m),3.07(1H,t,J=5.5Hz),1.82-1.60(2H,m),1.07(3H,t,J=7.5Hz);ESI-MS m/z595(MH+).
(S)-4-(4-アミノ-2-フルオロフェノキシ)-N-(1-ヒドロキシブタン-2-イル)-7-メトキシキノリン-6-カルボキサミド(41a)
化合物1の合成と同様に、化合物39c(300mg)、DMTMM・n水和物(329mg)、(S)-2-アミノブタン-1-オール(113μL)より、化合物41a(297mg、収率81%)を得た。
1H-NMR(DMSO-d6)δ:8.64(1H,d,J=5.1Hz),8.56(1H,s),8.12(1H,d,J=8.3Hz),7.51(1H,s),7.09(1H,t,J=9.0Hz),6.56(1H,dd,J=13.3Hz,J=2.3Hz),6.50-6.43(2H,m),5.52(2H,s),4.78(1H,t,J=5.5 Hz),4.01(3H,s),3.95-3.85(1H,m),3.56-3.48(1H,m),3.46-3.38(1H,m),1.74-1.62(1H,m),1.54-1.41(1H,m),0.93(3H,t,J=7.4Hz);ESI-MS m/z400(MH+).
化合物1dの合成と同様に、化合物41a(100mg)、3-フルオロフェニルアセチルチオイソシアネート(73mg)より、表記化合物41(115mg、収率78%)を得た。
1H-NMR (DMSO-d6)δ:12.44(1H,s),11.83(1H,s),8.69(1H,d,J=5.3Hz),8.57(1H,s),8.13(1H,d,J=8.3Hz),8.03(1H,d,J=12.2Hz),7.59-7.49(3H,m),7.44-7.36(1H,m),7.23-7.09(3H,m),6.52(1H,d,J=5.3Hz),4.77(1H,t,J=5.5),4.03(3H,s),3.93-3.84(1H,m),3.88(2H,s),3.54-3.48(1H,m),3.45-3.38(1H,m),1.72-1.62(1H,m),1.54-1.43(1H,m),0.93(3H,t,7.4Hz);ESI-MS m/z595(MH+)
4-(4-アミノ-2-フルオロフェノキシ)-N-(2-ヒドロキシ-2-メチルプロピル)-7-メトキシキノリン-6-カルボキサミド(42a)
化合物1の合成と同様に、39c(103mg)、DMTMM・n水和物(104mg)、1-アミノ-2-メチルプロパン-2-オール(42mg)より、化合物42a(66.3mg、収率53%)を得た。
1H-NMR(400Hz,CDCl3)δ:9.27(1H,s),8.64(1H,d,J=5.2Hz),8.26(1H,sbr),7.52(1H,s),7.02(1H,dd,J=8.4Hz),6.56(1H,dd,J=12.0Hz,2.8Hz),6.50(1H,ddd,J=8.8Hz,2.8Hz,0.8Hz),6.42(1H,dd,J=5.4Hz,1.2Hz),4.12(3H,s),3.82(1H,br),3.57(2H,d,J=6.0Hz),2.70(1H,sbr),1.33(6H,s);ESI-MS m/z400(MH+)
化合物1dの合成と同様に、化合物42a(55mg)、4-クロロフェニルアセチルチオイソシアネート(43.7mg)より、表記化合物42(41.3mg、収率49%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.45(1H,s),11.82(1H,s),8.71(1H,d,J=5.4Hz),8.67(1H,s),8.35(1H,t,J=6.1Hz),8.02(1H,d,J=11.0Hz),7.58-7.49(3H,m),7.43-7.32(4H,m),6.55(1H,d,J=5.4Hz),4.04(3H,s),3.84(2H,s),3.36-3.30(2H,m),1.98(1H,br),1.15(6H,s);ESI-MS m/z611,613(MH+)
(S)-4-(4-(3-(2-(4-クロロフェニル)アセチル)チオウレイド)-2-フルオロフェノキシ)-N-(1-ヒドロキシブタンー2-イル)-7-メトキシキノリン-6-カルボキサミド(43)
化合物1dの合成と同様に、化合物41a(63.0mg)、4-クロロフェニルアセチルチオイソシアネート(50.1mg)より、表記化合物43(29.9mg、収率31%)を得た。
1H-NMR(400Hz,CD3OD)δ:8.85(1H,s),8.63(1H,d,J=5.6Hz),8.07(1H,dd,J=12.0Hz,2.4Hz),7.52(1H,s),7.50-7.30(7H,m),6.60(1H,dd,J=5.4Hz,1.0Hz),4.11(3H,s),4.08-4.02(1H,mbr),3.76(2H,s),3.67(2H,dd,4.6Hz),3.27-3.22(1H,m),1.80-1.73(1H,m),1.65-1.57(1H,m),1.18(2H,s),1.04(3H,t,J=7.6Hz);ESI-MS m/z611,613(MH+)
4-(4-(3-(2-(2、6-ジフルオロフェニル)アセチル)チオウレイド)-2-フルオロフェノキシ)-7-メトキシキノリン-6-カルボキシリックアシッド(44a)
化合物1dの合成と同様に、化合物39c(98mg)、2,6-ジフルオロフェニルアセチルチオイソシアネート(128mg)とN,N-ジメチルアセトアミド(1.5mL)、トルエン(1.5mL)、エタノール(300μL)の混合溶媒を用いることにより、化合物44a(143mg、収率89%)を粗生成物で得た。
化合物1の合成と同様に、化合物44a(143mg)、DMTMM・n水和物(95mg)、2-モルホリノエタンアミン(51mg)、N,N-ジメチルアセトアミド(1mL)より、表記化合物44(103mg、収率60%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.35(1H,sbr),11.98(1H,sbr),8.70(1H,d,J=5.3Hz),8.70(1H,s),8.50(1H,t,J=5.4Hz),8.03(1H,dbr,J=13.5Hz),7.57(1H,s),7.61-7.39(3H,m),7.18-7.10(2H,m),6.53(1H,d,J=5.3Hz),4.07(3H,s),3.98(2H,s),3.62-3.58(4H,m),3.50-3.47(2H,m),3.47-3.20(4H,m),2.50-2.47(2H,m);ESI-MS m/z654(MH+)
4-(4-(3-(2-(2、6-ジフルオロフェニル)アセチルチオウレイド)-2-フルオロフェノキシ)-N-(2-ヒドロキシ-2-メチルプロピル)-7-メトキシキノリン-6-カルボキサミド(45)
化合物1の合成と同様に、化合物44a(101mg)、N,N-ジメチルアセトアミド(600μL)、DMTMM・n水和物(68mg)、1-アミノ-2-メチルプロパン-2-オール(31mg)より、表記化合物45(74mg、収率65%)を得た。
1H-NMR(400Hz,CDCl3)δ:12.38(1H,s),9.26(1H,s),8.69(1H,sbr),8.67(1H,d,J=5.4Hz),8.26 (1H,m),7.97(1H,dd,J=11.5Hz,2.7Hz),7.54(1H,s),7.43-7.32(2H,m),7.04-6.96(3H,m),6.44(1H,dd,J=5.2Hz,1,1Hz),4.13(3H,s),3.84(2H,s),3.57(2H,d,J=5.9Hz),2.58(1H,s),1.33(6H,s);ESI-MS m/z613(MH+).
4-(4-アミノ-2-フルオロフェノキシ)-7-メトキシ-N-メチルキノリン-6-カルボキサミド(46a)
化合物39b(100mg)をN-メチルピペリジン-2-オン(250μL)に溶解させ、40%メチルアミンメタノール溶液(250μL)を投入し、40度にて16時間攪拌した。反応液に水を投入して生じた沈殿を濾取することにより、化合物46a(63.7mg、収率64%)を得た。
1H-NMR(400Hz,CDCl3)δ:9.28(1H,s),8.63(1H,d,J=5.4Hz),7.84(1H,br),7.50(1H,s),7.02(1H,t,J=8.6Hz),6.56(1H,dd,J=12.0Hz,2.4Hz),6.50(1H,ddd,J=8.4Hz,2.8Hz,0.8Hz),6.43(1H,dd,J=5.2Hz,1.2Hz),4.11(3H,s),3.83,3.80(2H,br),3.08(3H,d,J=5.0Hz);ESI-MS m/z342(MH+).
化合物1dの合成と同様に、化合物46a(50.0mg)、3-メトキシフェニルアセチルイソチオシアネート(45.5mg)より、表記化合物46(40.1mg、収率50%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.49(1H,s),11.79(1H,s),8.70(1H,d,J=5.4Hz),8.59(1H,s),8.37(1H,d,J=4.2Hz),8.03(1H,dd,J=12.0Hz,2.4Hz),7.58-7.49(3H,m),7.42-7.33(2H,m),7.22-7.17(2H,m),6.54(1H,d,J=4.4Hz),4.02(3H,s),3.79(2H,s),3.75(3H,s),2.83(3H,d,J=4.8Hz);ESI-MS m/z549(MH+)
4-(2-フルオロ-4-(3-(2-(4-トリフルオロメチルフェニル)アセチル)チオウレイド)フェノキシ)-7-メトキシ-N-メチルキノリン-6-カルボキサミド(47)
化合物1dの合成と同様に、化合物46a(50.0mg)、4-トリフルオロメチルフェニルアセチルイソチオシアネート(53.9mg)より表記化合物47(41.2mg、収率48%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.42(1H,s),11.87(1H,s),8.69(1H,d,J=5.2Hz),8.59(1H,s),8.36(1H,d,J=4.8Hz),8.02(1H,dd,J=12.0Hz,2.0Hz),7.72(2H,d,J=8.4Hz),7.60-7.47(5H,m),6.52(1H,d,J=5.2Hz),4.02(3H,s),3.96(2H,s),2.83(3H,d,J=4.8Hz);ESI-MS m/z587(MH+)
メチル 4-(2-クロロ-4-ニトロフェノキシ)-7-メトキシキノリン-6-カルボキシレート(48a)
化合物1aの合成と同様に、メチル 4-クロロ-7-メトキシキノリン-6-カルボキシレート(350mg)、2-クロロ-4-ニトロフェノール(240mg)、N,N-ジイソプロピルエチルアミン(484μL)、N-メチルピロリジン-2-オン(1.5mL)より、化合物48a(130mg、収率24%)を得た。
1H-NMR(400Hz,CDCl3)δ:8.73(1H,s),8.73(1H,d,J=5.2Hz),8.48(1H,d,J=2.8Hz),8.25(1H,dd,J=8.8Hz,2.4Hz),7.55(1H,s),7.35(1H,d,J=8.8Hz),6.42(1H,d,J=4.8Hz),4.07(3H,s),3.98(3H,s);ESI-MS m/z389,391(MH+)
化合物1cの合成と同様に、化合物48a(111mg)、水-メタノール-テトラヒドロフラン(1:1:1)の混合溶液(5mL)、鉄粉(49.7mg)、塩化アンモニウム(111mg)より、化合物48b(31.2mg、収率31%)を粗生成物で得た。
ESI-MS m/z359,361(MH+)
化合物46aと同様に化合物48b(29.0mg)、40%メチルアミン水溶液(200μL)、N-メチルピロリジン-2-オン(200μL)より、化合物48c(27.1mg、収率94%)を得た。
1H-NMR(400Hz,CDCl3)δ:9.30(1H,s),8.61(1H,d,J=5.6Hz),7.84(1H,br),7.51(1H,s),7.02(1H,d,J=8.4Hz),6.83(1H,d,J=2.8Hz),6.64(1H,dd,J=8.4Hz,2.8Hz),6.32(1H,dd,J=5.4Hz),4.11(3H,s),3.78(2H,br),3.08(3H,d,J=6.0Hz);ESI-MS m/z358,360(MH+)
化合物1dの合成と同様に、化合物48c(24.0mg)、フェニルアセチルチオイソシアネート(17.8mg)より、表記化合物48(28.1mg、収率79%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.49(1H,s),11.85(1H,s),8.94(1H,d,J=6.0Hz),8.69(1H,s),8.47(1H,d,J=4.8Hz),8.21(1H,d,J=1.6Hz),7.78(1H,dd,J=8.6Hz,2.0Hz),7.61(1H,d,J=8.8Hz),7.59(1H,s),7.35-7.13(5H,m),6.69(1H,d,J=5.8Hz),4.07(3H,s),3.83(2H,s),2.84(3H,d,J=4.4Hz);ESI-MS m/z535,537(MH+)
メチル 4-(3-フルオロ-4-ニトロフェノキシ)-7-メトキシキノリン-6-カルボキシレート(49a)
化合物1aの合成と同様に、メチル 4-クロロ-7-メトキシキノリン-6-カルボキシレート(300mg)、3-フルオロ-4-ニトロフェノール(225mg)、N,N-ジイソプロピルエチルアミン(415μL)、N-メチルピロリジン-2-オン(1.5mL)より、化合物49a(112mg、収率25%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:8.82(1H,d,J=5.1Hz),8.45(1H,s),7.67(1H,dd,J=12.2Hz,2.7Hz),7.59(1H,s),7.32(1H,dd,J=8.8Hz,2.7Hz),6.83-6.74(1H,m),3.98(3H,s),3.84(3H,s);ESI-MS m/z373(MH+).
化合物1bの合成と同様に化合物49a(102mg)、鉄粉(76.5mg)、塩化アンモニウム(100mg)より、化合物49b(59.7mg、収率64%)を得た。
1H-NMR(400Hz,CDCl3)δ:8.79(1H,s),8.63(1H,d,J=5.2Hz),7.49(1H,s),6.91-6.80(3H,m),6.44(1H,d,J=5.2Hz),4.05(3H,s),3.97(3H,s),3.78,3.75(2H,br);ESI-MS m/z343(MH+)
化合物46aの合成と同様に、化合物49b(50.5mg)、40%メチルアミン水溶液(500μL)、N-メチルピロリジン-2-オン(500μL)より、化合物49c(31.2mg、収率62%)を得た。
1H-NMR(400Hz,CDCl3)δ:9.24(1H,s),8.62(1H,d,J=5.6Hz),7.86(1H,sbr),7.50(1H,s),6.90-6.79(3H,m),6.46(1H,d,J=5.2Hz),4.11(3H,s),3.76,3.74(2H,br),3.08(3H,d,J=5.0Hz);ESI-MS m/z342(MH+)
化合物1dの合成と同様に、化合物49c(25.0mg)、フェニルアセチルチオイソシアネート(19.5mg)より、表記化合物49(13.5mg、収率36%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.51(1H,s),11.89(1H,s),8.71(1H,d,J=4.8Hz),8.55(1H,s),8.34(1H,d,J=4.8Hz),8.06(1H,dd,J=8.8Hz),7.53(1H,s),7.42(1H,dd,J=10.8Hz,2.8Hz),7.37-7.25(5H,m),7.19-7.15(1H,m),6.62(1H,d,J=5.6Hz),4.01(3H,s),3.83(2H,s),2.82(3H,d,J=4.8Hz);ESI-MS m/z519(MH+)
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N,N-ジメチルキノリン-6-カルボキサミド(50)
化合物1の合成と同様に、化合物1e(285mg)、50%ジメチルアミン水溶液(147μL)、DMTMM・n水和物(174mg)より、表記化合物50(256mg、収率91%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.49(1H,s),11.81(1H,s),8.66(1H,dd,J=5.4Hz,1.2Hz),8.06(1H,d,J=1.0Hz),8.01(1H,d,J=12.4Hz),7.56-7.47(2H,m),7.52(1H,s),7.38-7.32(4H,m),7.31-7.25(1H,m),6.52(1H,d,J=5.1Hz),3.97(3H,d,J=0.8Hz),3.83(2H,s),3.01(3H,d,J=1.0Hz),2.79(3H,d,J=1.2Hz);ESI-MS m/z533(MH+)
N-(3-フルオロ-4-(7-メトキシ-6-(4-(ピロリジン-1-イル)ピペリジン-1-カルボニル)キノリン-4-イルオキシ)フェニルカルバモチオイル)-2-フェニルアセタミド(51)
化合物1の合成と同様に、化合物1e(27.6mg)、4-(ピロリジン-1-イル)ピペリジン(13.8mg)、DMTMM・n水和物(18.1mg)より、表記化合物51(14.1mg、収率39%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.50(1H,s),11.83(1H,s),8.68(1H,d,J=5.1Hz),8.08(1H,d,J=14.1),8.02(1H,d,J=12.4Hz),7.58-7.45(2H,m),7.53(1H,s),7.40-7.33(4H,m),7.33-7.26(1H,m),6.53(1H,dd,J=4.6Hz),4.40(1H,d,J=11.7Hz),3.98(3H,d,J=9.3Hz),3.84(2H,s),3.10-2.90(2H,m),2.75-2.60(4H,m),2.05-1.92(1H,m),1.85-1.67(6H,m),1.55-1.20(3H,m);ESI-MS m/z656(MH+)
N-(3-フルオロ-4-(6-(3-ヒドロキシピロリジン-1-カルボニル)-7-メトキシキノリン-4-イルオキシ)フェニルカルバモチオイル)-2-フェニルアセタミド(52)
化合物1の合成と同様に、化合物1e(20.0mg)、ピロリジン-3-オール(9.3mg)、DMTMM・n水和物(11.8mg)より、表記化合物52(15.0mg、収率71%)を得た。
1H-NMR(400Hz,DMSO-d6)δ:12.51(1H,s),11.85(1H,s),8.93(1H,d,J=6.4Hz),8.31(1H,s),8.10(1H,d,J=12.4Hz),7.71(1H,s),7.61-7.47(2H,m),7.40-7.18(5H,m),6.87(1H,d,J=6.1Hz),4.33(1H,br),4.23(1H,br),4.03(3H,s),3.83(2H,s),2.00-1.80(4H,m),1.77-1.72(2H,m);ESI-MS m/z575(MH+)
4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-6,7-ジメトキシ-キノリン-6-カルボキサミド(比較化合物1)
国際公開2006-104161号公報に記載の方法に準じて合成した。
c-Metリン酸化酵素に対する阻害活性は以下の方法に従って測定した。
A法)AlphaScreenを利用したアッセイ方法
Clin Cancer Res.vol.8,(2),pp620-7(2002)に生体内の基質として報告されている、Pyk2のリン酸化部位Tyr402を含むビオチン化ペプチドを基質に、反応用緩衝液(60mM HEPES pH7.5、5mM MgCl2、5mM MnCl2、3μM Na3VO4、1.25mM DTT)中、本発明化合物の存在下、c-Met(08-051,Carna bio Co.,Ltd)と終濃度20μMでATPを加え、室温で20分間反応させた。最終濃度50mMになるようEDTAを加えることで反応を停止した。チロシン化リン酸化認識抗体が結合したAlphaScreenTMPhosphotyrosine(P-Tyr-100)Assay Kit(6760620C,Perkin Elmer)に従い調整した検出液を添加し、室温で1時間反応した後の蛍光量をEnVisionTMマルチラベルカウンター(Perkin Elmer)で測定した。リン酸化反応を50%抑制することのできる化合物濃度をIC50値(μM)と定義し以下の表に示した。
脱リン酸化酵素阻害剤カクテル(PhosSTOP,#4906837,Roche)及びタンパク分解酵素阻害剤カクテル(Complete,Mini,EDTA-free,#1836170,Roche)を添加した反応用緩衝液(100mM HEPES pH7.5、10mM MgCl2、0.003% Brij-35、0.04%Tween、1mM DTT)を調製した。本発明化合物の存在下、反応緩衝液にリコンビナントc-Met(自社精製品)、最終濃度1.5μMの蛍光標識c-Met基質ペプチド(FL-Peptide2,#760346,Caliper LifeSciences)と最終濃度43μMでATPを添加し、28℃で90分間反応させた。最終濃度10mMになるようにEDTAを加え反応を停止した。DeskTop profiler(#119900,Caliper LifeSciences)を用いて、基質とリン酸化物それぞれの蛍光値を測定し、生成したリン酸化物量を求めた。リン酸化物の生成を50%抑制することのできる化合物濃度をIC50値(μM)と定義し以下の表に示した。
10%のFBSを含むRPMI1640(和光純薬工業社製)、又はDMEM培地(ナカライテスク社製)中に浮遊させたNUGC4細胞浮遊液を、96ウェル平底マイクロプレートの各ウェルに2×103個(0.1mL)ずつ播種し、5%炭酸ガス含有の培養器中37℃で1日培養した。本発明化合物、及び比較化合物1をジメチルスルホキシドにて30mMの濃度に溶解し、さらに、10%のFBSを含むRPMI1640又はDMEM培地を用いて、被験化合物の最終濃度がそれぞれ60、20、6、2、0.6、0.2μMになるように希釈を行った。これをNUGC4細胞の培養プレートの各ウェルに0.1mLずつ加え、5%炭酸ガス含有の培養器中37℃で3日間培養した。培養後、25%グルタルアルデヒド水溶液(ナカライテスク社製)を各ウェルに20μLずつ添加し、室温で20分放置し、細胞を固定した。その後、プレートを水にて洗浄し乾燥させた。0.05%クリスタルバイオレット/20%メタノール水溶液(和光純薬工業社製)を各ウェルに100μLずつ添加後、室温で20分放置し、細胞を染色した。その後、プレートを水道水にて洗浄し乾燥させた。各ウェルに0.05M NaH2PO4/エタノール(1/1=v/v)100μLを加え、クリスタルバイオレットを抽出した。抽出されたクリスタルバイオレットの540nmにおける吸光度をマイクロプレートリーダーで測定し、生細胞数の指標とした。以下の式より抑制率を算出し、50%抑制する被験化合物の濃度(IC50(μM))を求めた。
抑制率(%)=(C-T)/C×100
T:被験化合物を添加したウェルの吸光度
C:被験化合物を添加しなかったウェルの吸光度
c-Metが低発現である腫瘍細胞(HCT-116)、及び正常細胞(HAOSMC(ヒト大動脈平滑筋細胞)、HMEC(ヒト皮膚微小血管内皮細胞))についても同様の方法を用いてin vitroでの細胞増殖抑制試験を実施した。これらの細胞株に対するIC50は、比較化合物1が15~24μMであったのに対し、本発明化合物は大半が30μM以上であり、c-Met低発現株に対しては、比較化合物1と同等又はそれ以下の細胞増殖抑制活性を示すことが確認された。すなわちc-Met過剰発現である癌細胞に対する細胞増殖抑制効果と、c-Metが低発現である細胞又は正常細胞に対する細胞増殖抑制効果との乖離幅(ratio)が比較化合物1よりも極めて大きいことから、本発明化合物は優れた選択的細胞増殖抑制活性を有していることが確認できた。
抗腫瘍効果を評価するための投与用量を設定するため、ヌードマウス(n=3~5/群)に対して本発明化合物及び比較化合物1を14日間、1日1回連日経口投与して体重推移を評価指標として最大耐薬用量を算出した。
投与期間中のマウスの体重変化率(Body weight change;BWC%)を算出し、各化合物投与群の平均BWCが10%以上の減少を示した場合、薬剤による毒性発現用量と判断し、最大耐薬用量としては、毒性発現用量より2倍低い用量を設定した。
マウス個体のBWCは、以下の式に従って算出し、各群の平均BWC値の投与期間中の推移を図1に示した。
BWC(%)=([(体重計測日のマウス体重)―(群分け時のマウス体重)]/(群分け時のマウス体重))×100
一方、本発明化合物は、200mg/kgを投与した群において体重減少が認められず、さらに図1に示されるように400mg/kg投与した群においても、体重減少を示さなかった。そこで本発明化合物について、試験例4(抗腫瘍効果の評価)については投与用量を400mg/kgに設定した。
ヒト胃癌細胞(NUGC4)(ATCCから入手)をヌードマウスの皮下に移植し、腫瘍が生着したヌードマウスの腫瘍体積が100~300mm3程度になった時点で、各群の腫瘍体積の平均が均一になるよう無作為層別化により1群5~6匹を割付(1日目)、本発明化合物及び比較化合物1を14日間、1日1回連日経口投与した。
投与用量は、試験例3の結果より、比較化合物1では本試験の投与期間である14日間での最大耐薬用量(投与期間中の体重減少が10%未満となる最大投与用量)の100mg/kg/dayを、本発明化合物では400mg/kg/dayを使用した。
各被験化合物投与における腫瘍の経時的増殖推移を比較するため、腫瘍の増殖割合として群分け時の腫瘍体積を1とした相対腫瘍体積(Relative tumor weight;RTV)を以下の式に従って算出し、各個体のRTVの平均値の推移を図2に示した。
RTV=(腫瘍体積計測日の腫瘍体積)/(群分け時の腫瘍体積)
最終評価日の本発明化合物投与群の平均RTV値が、比較化合物1の投与群の平均RTV値より小さく、かつ統計的有意差(Student-t検定)を示した場合に、本発明化合物は、比較化合物1よりも有意に有効であると判定し、図2に*印で示した。
Claims (12)
- 一般式(I)
R3は、C1-6アルキル基を示し;
R4、R5及びR6は、同一又は異なって、水素原子、ハロゲン原子、置換基を有していてもよいC1-6アルキル基、C1-6アルコキシ基、C1-6アルキルアミノ基、置換基を有していてもよい芳香族炭化水素基、又は置換基を有していてもよい飽和又は不飽和複素環基を示すか、R5及びR6は結合するフェニル環と一緒になって環を形成していてもよい。)
で表されるアシルチオウレア化合物又はその塩。 - R1は水素原子又はC1-3アルキル基を示し、R2は水素原子、置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいC6-14芳香族炭化水素基、又は置換基を有していてもよい飽和又は不飽和複素環基を示すか、R1及びR2は結合する窒素原子と一緒になって置換基を有していてもよい含窒素飽和複素環基を示し、R3はC1-3アルキル基を示し、R4はハロゲン原子を示し、R5及びR6は、同一又は異なって、水素原子、ハロゲン原子、置換基としてハロゲン原子を有していてもよいC1-3アルキル基、又はC1-3アルコキシ基を示す、請求項1記載のアシルチオウレア化合物又はその塩。
- R1は水素原子又はメチル基を示し、R2は置換基を有していてもよいC1-6アルキル基、置換基を有していてもよいフェニル基、又は置換基を有していてもよい窒素原子又は硫黄原子を1~2個有する5~7員の複素環基を示すか、R1及びR2は結合する窒素原子と一緒になって置換基を有していてもよいピロリジニル基、又は置換基を有していてもよいピペリジニル基を示し、R3はメチル基を示し、R4はフッ素原子又は塩素原子を示し、R5は水素原子又はハロゲン原子を示し、R6は水素原子、ハロゲン原子、トリフルオロメチル基又はメトキシ基を示す、請求項1記載のアシルチオウレア化合物又はその塩。
- R1は水素原子を示し、R2は置換基を有していてもよいC1-6アルキル基を示し、該置換基として、ヒドロキシル基、C3-10シクロアルキル基、置換基を有していてもよいC1-6アルコキシ基、置換基を有していてもよいC1-6アルキルアミノ基、C1-6アルカノイルアミノ基、C1-6アルキルスルホニル基、置換基を有していてもよいC6-14芳香族炭化水素基、置換基を有していてもよい飽和又は不飽和複素環基、置換基を有していてもよい飽和又は不飽和複素環カルボニル基、置換基を有していてもよいC1-6アルキルアミノカルボニル基、置換基を有していてもよい飽和又は不飽和複素環カルボニル基のいずれかを示し、R3はメチル基を示し、R4はフッ素原子、又は塩素原子を示し、R5は水素原子を示し、R6は水素原子、フッ素原子、又は塩素原子を示す、請求項1記載のアシルチオウレア化合物又はその塩。
- R2が置換基を有していてもよいC1-4アルキル基であり、該置換基が、ヒドロキシル基、シクロヘキシル基、C1-3アルコキシ基、C1-6アルキルアミノ基、アセチルアミノ基、メチルスルホニル基、フェニル基、窒素及び/又は酸素原子を1~4個有する5~7員の複素環基、C1-6アルキルアミノカルボニル基、窒素及び/又は酸素原子を1~2個有する5~7員の複素環カルボニル基のいずれかであって、該C1-3アルコキシ基はさらに置換基としてヒドロキシル基を有していてもよく、該C1-6アルキルアミノカルボニル基はさらに置換基としてヒドロキシル基、又はC1-6アルコキシ基を有していてもよく、該複素環基はさらに置換基としてC1-6アルキル基、又はオキソ基を有していてもよく、該複素環カルボニル基はさらに置換基としてハロゲン原子、又はヒドロキシル基を有していてもよいC1-6アルキル基を有していてもよい、請求項1記載のアシルチオウレア化合物又はその塩。
- R2がメチル基、エチル基、n-プロピル基、イソプロピル基、n-ブチル基、又はsec-ブチル基であって、該アルキル基上の置換基が、ヒドロキシル基、シクロヘキシル基、メトキシ基、エトキシ基、イソプロピルオキシ基、ジエチルアミノ基、アセチルアミノ基、メチルスルホニル基、フェニル基、ピロリジニル基、モルホリノ基、ジオキソラン基、テトラヒドロピラニル基、ピリジル基、トリアゾリル基、エチルアミノカルボニル基、ジメチルアミノカルボニル基、メチルブチルアミノカルボニル基、ピロリジニルカルボニル基、モルホリノカルボニル基のいずれかであって、該アルコキシ基はさらに置換基としてヒドロキシル基を有していてもよく、該複素環基はさらに置換基としてメチル基、又はオキソ基を有していてもよく、該アルキルアミノカルボニル基はさらに置換基としてヒドロキシル基、又はメトキシ基を有していてもよく、該複素環カルボニル基はさらに置換基としてフッ素原子、ヒドロキシル基を有していてもよいメチル基を有していてもよい、請求項1記載のアシルチオウレア化合物又はその塩。
- 以下の群から選択される、請求項1に記載のアシルチオウレア化合物又はその塩:
・4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-メチルキノリン-6-カルボキサミド
・4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(メトキシエチル)キノリン-6-カルボキサミド
・4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(2-モルホリノエチル)キノリン-6-カルボキサミド
・4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(2-モルホリノ-2-オキソエチル)キノリン-6-カルボキサミド
・4-(2-フルオロ-4-(3-(2-(4-フルオロフェニル)アセチル)チオウレイド)フェノキシ)-N-(2-ヒドロキシブチル)-7-メトキシキノリン-6-カルボキサミド
・4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-N-(2-ヒドロキシ-2-メチルプロピル)-7-メトキシキノリン-6-カルボキサミド
・(S)-4-(2-フルオロ-4-(3-(2-フェニルアセチル)チオウレイド)フェノキシ)-N-(1-ヒドロキシブタン-2-イル)-7-メトキシキノリン-6-カルボキサミド
・4-(2-フルオロ-4-(3-(2-(4-フルオロフェニル)アセチル)チオウレイド)フェノキシ)-7-メトキシ-N-(2-モルホリノエチル)キノリン-6-カルボキサミド
・(S)-4-(2-フルオロ-4-(3-(2-(4-フルオロフェニル)アセチル)チオウレイド)フェノキシ)-N-(1-ヒドロキシブタン-2-イル)-7-メトキシキノリン-6-カルボキサミド
・(S)-4-(2-フルオロ-4-(3-(2-(2-フルオロフェニル)アセチル)チオウレイド)フェノキシ)-N-(1-ヒドロキシブタン-2-イル)-7-メトキシキノリン-6-カルボキサミド
・(S)-4-(4-(3-(2-(4-クロロフェニル)アセチル)チオウレイド)-2-フルオロフェノキシ)-N-(1-ヒドロキシブタン-2-イル)-7-メトキシキノリン-6-カルボキサミド - 請求項1乃至7のいずれか1項記載のアシルチオウレア化合物又はその塩を有効成分とする医薬。
- 請求項1乃至7のいずれか1項記載のアシルチオウレア化合物又はその塩を有効成分とする抗腫瘍剤。
- 請求項1乃至7のいずれか1項記載のアシルチオウレア化合物又はその塩、及び薬学的に許容された担体を含有する医薬組成物。
- 抗腫瘍剤製造のための、請求項1乃至7のいずれか1項記載のアシルチオウレア化合物又はその塩の使用。
- 請求項1乃至7のいずれか1項記載のアシルチオウレア化合物又はその塩の有効量を投与することを特徴とする癌治療法。
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL09730440T PL2287155T3 (pl) | 2008-04-10 | 2009-04-09 | Acylotiomocznik lub jego sól oraz jego zastosowanie |
CA2720552A CA2720552C (en) | 2008-04-10 | 2009-04-09 | Acylthiourea compound or salt thereof, and use thereof |
SI200930710T SI2287155T1 (sl) | 2008-04-10 | 2009-04-09 | Aciltiosečninska spojina ali njena sol in njena uporaba |
RU2010145526/04A RU2503664C2 (ru) | 2008-04-10 | 2009-04-09 | Производное ацилтиомочевины или его соль, и его применение |
JP2010507175A JP4667537B2 (ja) | 2008-04-10 | 2009-04-09 | アシルチオウレア化合物又はその塩、及びその用途 |
EP09730440.6A EP2287155B1 (en) | 2008-04-10 | 2009-04-09 | Acylthiourea compound or salt thereof, and use thereof |
AU2009234978A AU2009234978B2 (en) | 2008-04-10 | 2009-04-09 | Acylthiourea Compound or Salt Thereof, and use thereof |
BRPI0911679A BRPI0911679B8 (pt) | 2008-04-10 | 2009-04-09 | composto aciltioureia ou um sal do mesmo, uso do dito composto para tratar câncer, bem como agente farmacêutico, agente antitumoral e composição farmacêutica compreendendo dito composto |
US12/937,312 US8304427B2 (en) | 2008-04-10 | 2009-04-09 | Acylthiourea compound or salt thereof, and use thereof |
DK09730440.6T DK2287155T3 (da) | 2008-04-10 | 2009-04-09 | Acylthiourea-forbindelse eller salt deraf samt anvendelse deraf |
ES09730440T ES2423851T3 (es) | 2008-04-10 | 2009-04-09 | Compuesto de aciltiourea o sal del mismo y uso del mismo |
MX2010011097A MX2010011097A (es) | 2008-04-10 | 2009-04-09 | Compuesto de aciltiourea o sal del mismo, y uso del mismo. |
CN2009801127609A CN101998951B (zh) | 2008-04-10 | 2009-04-09 | 酰基硫脲化合物或其盐及其用途 |
KR1020107022154A KR101414931B1 (ko) | 2008-04-10 | 2009-04-09 | 아실티오우레아 화합물 또는 그 염 및 그 용도 |
HK11105356.4A HK1151288A1 (en) | 2008-04-10 | 2011-05-30 | Acylthiourea compound or salt thereof, and use of the compound or the salt |
HRP20130984AT HRP20130984T1 (hr) | 2008-04-10 | 2013-10-17 | Spoj aciltiouree ili njegove soli, i njegova primjena |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-102832 | 2008-04-10 | ||
JP2008102832 | 2008-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009125597A1 true WO2009125597A1 (ja) | 2009-10-15 |
Family
ID=41161733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/001655 WO2009125597A1 (ja) | 2008-04-10 | 2009-04-09 | アシルチオウレア化合物又はその塩、及びその用途 |
Country Status (20)
Country | Link |
---|---|
US (1) | US8304427B2 (ja) |
EP (1) | EP2287155B1 (ja) |
JP (1) | JP4667537B2 (ja) |
KR (1) | KR101414931B1 (ja) |
CN (1) | CN101998951B (ja) |
AU (1) | AU2009234978B2 (ja) |
BR (1) | BRPI0911679B8 (ja) |
CA (1) | CA2720552C (ja) |
CY (1) | CY1114166T1 (ja) |
DK (1) | DK2287155T3 (ja) |
ES (1) | ES2423851T3 (ja) |
HK (1) | HK1151288A1 (ja) |
HR (1) | HRP20130984T1 (ja) |
MX (1) | MX2010011097A (ja) |
PL (1) | PL2287155T3 (ja) |
PT (1) | PT2287155E (ja) |
RU (1) | RU2503664C2 (ja) |
SI (1) | SI2287155T1 (ja) |
TW (1) | TWI438193B (ja) |
WO (1) | WO2009125597A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012008563A1 (ja) | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | 含窒素芳香族複素環誘導体 |
US8232294B2 (en) | 2009-03-21 | 2012-07-31 | Ning Xi | Amino ester derivatives, sailts thereof and methods of use |
WO2012121273A1 (ja) * | 2011-03-07 | 2012-09-13 | 味の素株式会社 | 塩味増強剤 |
US8293897B2 (en) | 2008-10-14 | 2012-10-23 | Ning Xi | Compounds comprising a spiro-ring and methods of use |
WO2013100014A1 (ja) | 2011-12-28 | 2013-07-04 | 大鵬薬品工業株式会社 | 抗腫瘍剤の効果増強剤 |
WO2013111798A1 (ja) | 2012-01-27 | 2013-08-01 | 国立大学法人 富山大学 | セリンラセマーゼ阻害剤 |
WO2015046484A1 (ja) | 2013-09-30 | 2015-04-02 | 国立大学法人東京農工大学 | 骨粗鬆症治療剤 |
WO2016175305A1 (ja) * | 2015-04-30 | 2016-11-03 | 大鵬薬品工業株式会社 | アシルチオウレア化合物のメシル酸塩及びその結晶並びにそれらの製造方法 |
WO2016208744A1 (ja) * | 2015-06-25 | 2016-12-29 | 大鵬薬品工業株式会社 | 線維症治療剤 |
WO2018151177A1 (ja) | 2017-02-15 | 2018-08-23 | 大鵬薬品工業株式会社 | 医薬組成物 |
WO2019049956A1 (ja) | 2017-09-08 | 2019-03-14 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び抗腫瘍効果増強剤 |
JP2020037576A (ja) * | 2015-04-07 | 2020-03-12 | グアンドン・レイノーヴェント・バイオテック・カンパニー・リミテッド | チロシンキナーゼ阻害剤およびそれを含む医薬組成物 |
WO2020059744A1 (ja) | 2018-09-18 | 2020-03-26 | 大鵬薬品工業株式会社 | アシルチオウレア化合物とアビラテロンの併用療法 |
JPWO2021162096A1 (ja) * | 2020-02-14 | 2021-08-19 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9314253B2 (en) | 2008-07-01 | 2016-04-19 | Amendia, Inc. | Tissue modification devices and methods |
CN105601566A (zh) * | 2016-02-02 | 2016-05-25 | 张敏 | 一种护理烧伤后感染的药物组合物 |
WO2018028591A1 (zh) | 2016-08-09 | 2018-02-15 | 殷建明 | 一种喹啉衍生物及其用途 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001047890A1 (fr) | 1999-12-24 | 2001-07-05 | Kirin Beer Kabushiki Kaisha | Quinoline, derives de la quinazoline et medicaments contenant ces substances |
WO2002032872A1 (en) | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Nitrogenous aromatic ring compounds |
WO2003000660A1 (en) | 2001-06-22 | 2003-01-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same |
WO2005030140A2 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
US20050096358A1 (en) | 2002-03-28 | 2005-05-05 | Yang Gao | Substituted biaryl amides as C5A receptor modulators |
WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
WO2005082855A1 (ja) | 2004-02-27 | 2005-09-09 | Eisai Co., Ltd. | 新規ピリジン誘導体およびピリミジン誘導体(2) |
WO2005121125A1 (en) | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
WO2006104161A1 (ja) | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | c-Met自己リン酸化阻害作用を有するチエノピリジン誘導体、キノリン誘導体、およびキナゾリン誘導体 |
WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL102548A (en) * | 1991-08-02 | 1998-08-16 | Medivir Ab | Use of painting derivatives in the preparation of drugs for VIH inhibition and treatment of SDIA and new compounds |
-
2009
- 2009-04-09 CA CA2720552A patent/CA2720552C/en active Active
- 2009-04-09 TW TW098111876A patent/TWI438193B/zh active
- 2009-04-09 DK DK09730440.6T patent/DK2287155T3/da active
- 2009-04-09 SI SI200930710T patent/SI2287155T1/sl unknown
- 2009-04-09 AU AU2009234978A patent/AU2009234978B2/en active Active
- 2009-04-09 KR KR1020107022154A patent/KR101414931B1/ko active IP Right Grant
- 2009-04-09 CN CN2009801127609A patent/CN101998951B/zh active Active
- 2009-04-09 ES ES09730440T patent/ES2423851T3/es active Active
- 2009-04-09 EP EP09730440.6A patent/EP2287155B1/en active Active
- 2009-04-09 BR BRPI0911679A patent/BRPI0911679B8/pt active IP Right Grant
- 2009-04-09 MX MX2010011097A patent/MX2010011097A/es active IP Right Grant
- 2009-04-09 PL PL09730440T patent/PL2287155T3/pl unknown
- 2009-04-09 WO PCT/JP2009/001655 patent/WO2009125597A1/ja active Application Filing
- 2009-04-09 RU RU2010145526/04A patent/RU2503664C2/ru active
- 2009-04-09 PT PT97304406T patent/PT2287155E/pt unknown
- 2009-04-09 US US12/937,312 patent/US8304427B2/en active Active
- 2009-04-09 JP JP2010507175A patent/JP4667537B2/ja active Active
-
2011
- 2011-05-30 HK HK11105356.4A patent/HK1151288A1/xx unknown
-
2013
- 2013-07-23 CY CY20131100625T patent/CY1114166T1/el unknown
- 2013-10-17 HR HRP20130984AT patent/HRP20130984T1/hr unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001047890A1 (fr) | 1999-12-24 | 2001-07-05 | Kirin Beer Kabushiki Kaisha | Quinoline, derives de la quinazoline et medicaments contenant ces substances |
WO2002032872A1 (en) | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Nitrogenous aromatic ring compounds |
JP2005272474A (ja) * | 2000-10-20 | 2005-10-06 | Eisai Co Ltd | 含窒素芳香環誘導体 |
WO2003000660A1 (en) | 2001-06-22 | 2003-01-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same |
US20050096358A1 (en) | 2002-03-28 | 2005-05-05 | Yang Gao | Substituted biaryl amides as C5A receptor modulators |
WO2005030140A2 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
WO2005082855A1 (ja) | 2004-02-27 | 2005-09-09 | Eisai Co., Ltd. | 新規ピリジン誘導体およびピリミジン誘導体(2) |
WO2005121125A1 (en) | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
WO2006104161A1 (ja) | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | c-Met自己リン酸化阻害作用を有するチエノピリジン誘導体、キノリン誘導体、およびキナゾリン誘導体 |
WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
Non-Patent Citations (13)
Title |
---|
"Development of Drugs", vol. 7, 1990, HIROKAWA SHOTEN, pages: 163 - 198 |
AM. J. PATHOL., vol. 158, 2001, pages 1111 - 1120 |
ANGEW. CHEM. INT. ED., vol. 46, no. 25, 2007, pages 4751 - 4753 |
BIOORG. MED. CHEM. LETT., vol. 18, 2008, pages 2793 - 2798 |
CANCER LETTERS, vol. 225, 2005, pages 1 - 26 |
CANCER, vol. 85, no. 9, 1999, pages 1894 - 1902 |
CLIN. CANCER RES., vol. 8, no. 2, 2002, pages 620 - 7 |
J. CELL BIOL., vol. 111, 1990, pages 2097 - 2108 |
J. MED. CHEM., vol. 31, no. 11, 1988, pages 2145 - 2152 |
J. ORG. CHEM., vol. 54, no. 24, 1989, pages 5651 - 5654 |
JPN. J. CANCER RES., vol. 87, 1996, pages 1063 - 1069 |
See also references of EP2287155A4 * |
SEMIN CANCER BIOL, vol. 11, 2001, pages 153 - 165 |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8293897B2 (en) | 2008-10-14 | 2012-10-23 | Ning Xi | Compounds comprising a spiro-ring and methods of use |
US8426585B2 (en) | 2008-10-14 | 2013-04-23 | Ning Xi | Compounds comprising a spiro-ring |
US8232294B2 (en) | 2009-03-21 | 2012-07-31 | Ning Xi | Amino ester derivatives, sailts thereof and methods of use |
WO2012008563A1 (ja) | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | 含窒素芳香族複素環誘導体 |
WO2012121273A1 (ja) * | 2011-03-07 | 2012-09-13 | 味の素株式会社 | 塩味増強剤 |
JPWO2013100014A1 (ja) * | 2011-12-28 | 2015-05-11 | 大鵬薬品工業株式会社 | 抗腫瘍剤の効果増強剤 |
KR20140096375A (ko) | 2011-12-28 | 2014-08-05 | 다이호야쿠힌고교 가부시키가이샤 | 항종양제의 효과 증강제 |
WO2013100014A1 (ja) | 2011-12-28 | 2013-07-04 | 大鵬薬品工業株式会社 | 抗腫瘍剤の効果増強剤 |
WO2013111798A1 (ja) | 2012-01-27 | 2013-08-01 | 国立大学法人 富山大学 | セリンラセマーゼ阻害剤 |
WO2015046484A1 (ja) | 2013-09-30 | 2015-04-02 | 国立大学法人東京農工大学 | 骨粗鬆症治療剤 |
JPWO2015046484A1 (ja) * | 2013-09-30 | 2017-03-09 | 国立大学法人東京農工大学 | 骨粗鬆症治療剤 |
US9149471B2 (en) | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
JP2020037576A (ja) * | 2015-04-07 | 2020-03-12 | グアンドン・レイノーヴェント・バイオテック・カンパニー・リミテッド | チロシンキナーゼ阻害剤およびそれを含む医薬組成物 |
WO2016175305A1 (ja) * | 2015-04-30 | 2016-11-03 | 大鵬薬品工業株式会社 | アシルチオウレア化合物のメシル酸塩及びその結晶並びにそれらの製造方法 |
JPWO2016175305A1 (ja) * | 2015-04-30 | 2018-04-12 | 大鵬薬品工業株式会社 | アシルチオウレア化合物のメシル酸塩及びその結晶並びにそれらの製造方法 |
US10143688B2 (en) | 2015-04-30 | 2018-12-04 | Taiho Pharmaceutical Co., Ltd. | Mesylic acid salt of acylthiourea compound, crystal of the same, and process for producing these |
EP3973962A1 (en) | 2015-06-25 | 2022-03-30 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for fibrosis |
KR20180021682A (ko) | 2015-06-25 | 2018-03-05 | 다이호야쿠힌고교 가부시키가이샤 | 섬유증 치료제 |
US11690838B2 (en) | 2015-06-25 | 2023-07-04 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for fibrosis |
JP7258985B2 (ja) | 2015-06-25 | 2023-04-17 | 大鵬薬品工業株式会社 | 線維症治療剤 |
JP2022009994A (ja) * | 2015-06-25 | 2022-01-14 | 大鵬薬品工業株式会社 | 線維症治療剤 |
US10449189B2 (en) | 2015-06-25 | 2019-10-22 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for fibrosis |
WO2016208744A1 (ja) * | 2015-06-25 | 2016-12-29 | 大鵬薬品工業株式会社 | 線維症治療剤 |
US11191759B2 (en) | 2015-06-25 | 2021-12-07 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for fibrosis |
JP7498827B2 (ja) | 2015-06-25 | 2024-06-12 | 大鵬薬品工業株式会社 | 線維症治療剤 |
AU2016284531B2 (en) * | 2015-06-25 | 2020-06-04 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for fibrosis |
US10695340B2 (en) | 2015-06-25 | 2020-06-30 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for fibrosis |
RU2729630C2 (ru) * | 2015-06-25 | 2020-08-11 | Тайхо Фармасьютикал Ко., Лтд. | Терапевтическое средство для фиброза |
JPWO2016208744A1 (ja) * | 2015-06-25 | 2018-04-12 | 大鵬薬品工業株式会社 | 線維症治療剤 |
WO2018151177A1 (ja) | 2017-02-15 | 2018-08-23 | 大鵬薬品工業株式会社 | 医薬組成物 |
US11110062B2 (en) | 2017-02-15 | 2021-09-07 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition |
KR20210135354A (ko) | 2017-02-15 | 2021-11-12 | 다이호야쿠힌고교 가부시키가이샤 | 의약 조성물 |
KR20190113831A (ko) | 2017-02-15 | 2019-10-08 | 다이호야쿠힌고교 가부시키가이샤 | 의약 조성물 |
WO2019049956A1 (ja) | 2017-09-08 | 2019-03-14 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び抗腫瘍効果増強剤 |
KR20200037354A (ko) | 2017-09-08 | 2020-04-08 | 다이호야쿠힌고교 가부시키가이샤 | 항종양제 및 항종양 효과 증강제 |
AU2018329881B2 (en) * | 2017-09-08 | 2021-12-02 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent and antitumor effect potentiator |
JPWO2019049956A1 (ja) * | 2017-09-08 | 2020-10-01 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び抗腫瘍効果増強剤 |
JP7074760B2 (ja) | 2017-09-08 | 2022-05-24 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び抗腫瘍効果増強剤 |
WO2020059744A1 (ja) | 2018-09-18 | 2020-03-26 | 大鵬薬品工業株式会社 | アシルチオウレア化合物とアビラテロンの併用療法 |
KR20210060465A (ko) | 2018-09-18 | 2021-05-26 | 다이호야쿠힌고교 가부시키가이샤 | 아실티오우레아 화합물과 아비라테론의 병용 요법 |
WO2021162096A1 (ja) | 2020-02-14 | 2021-08-19 | 大鵬薬品工業株式会社 | アシルチオウレア化合物の製造方法 |
CN115103834A (zh) * | 2020-02-14 | 2022-09-23 | 大鹏药品工业株式会社 | 酰硫脲化合物的类缘物质 |
KR20220127857A (ko) | 2020-02-14 | 2022-09-20 | 다이호야쿠힌고교 가부시키가이샤 | 아실티오우레아 화합물의 제조 방법 |
JPWO2021162096A1 (ja) * | 2020-02-14 | 2021-08-19 | ||
JP7414947B2 (ja) | 2020-02-14 | 2024-01-16 | 大鵬薬品工業株式会社 | アシルチオウレア化合物の製造方法 |
EP4105200A4 (en) * | 2020-02-14 | 2024-01-24 | Taiho Pharmaceutical Co., Ltd. | METHOD FOR PRODUCING ACYLTHIOUREA COMPOUND |
WO2021162097A1 (ja) * | 2020-02-14 | 2021-08-19 | 大鵬薬品工業株式会社 | アシルチオウレア化合物の類縁物質 |
Also Published As
Publication number | Publication date |
---|---|
JP4667537B2 (ja) | 2011-04-13 |
SI2287155T1 (sl) | 2013-10-30 |
EP2287155B1 (en) | 2013-07-17 |
CA2720552A1 (en) | 2009-10-15 |
CY1114166T1 (el) | 2016-08-31 |
RU2503664C2 (ru) | 2014-01-10 |
US20110034439A1 (en) | 2011-02-10 |
RU2010145526A (ru) | 2012-05-20 |
PT2287155E (pt) | 2013-07-26 |
BRPI0911679A2 (pt) | 2015-10-13 |
HK1151288A1 (en) | 2012-01-27 |
BRPI0911679B8 (pt) | 2021-05-25 |
PL2287155T3 (pl) | 2013-12-31 |
AU2009234978A1 (en) | 2009-10-15 |
DK2287155T3 (da) | 2013-07-29 |
KR101414931B1 (ko) | 2014-07-04 |
TW201000451A (en) | 2010-01-01 |
HRP20130984T1 (hr) | 2013-11-22 |
US8304427B2 (en) | 2012-11-06 |
BRPI0911679B1 (pt) | 2020-09-29 |
TWI438193B (zh) | 2014-05-21 |
CN101998951A (zh) | 2011-03-30 |
JPWO2009125597A1 (ja) | 2011-08-04 |
CA2720552C (en) | 2016-06-14 |
MX2010011097A (es) | 2010-11-01 |
AU2009234978B2 (en) | 2014-03-06 |
KR20100132023A (ko) | 2010-12-16 |
ES2423851T3 (es) | 2013-09-24 |
EP2287155A4 (en) | 2012-05-09 |
CN101998951B (zh) | 2013-07-17 |
EP2287155A1 (en) | 2011-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4667537B2 (ja) | アシルチオウレア化合物又はその塩、及びその用途 | |
JP2019163290A (ja) | 新規グルタミナーゼ阻害剤 | |
US7709475B2 (en) | Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton | |
JP5770281B2 (ja) | c−METチロシンキナーゼ阻害薬として有用な新規な縮合複素環式誘導体 | |
KR20160132470A (ko) | 피페리딘-다이온 유도체 | |
JP2017524703A (ja) | 2,4−二置換7H−ピロロ[2,3−d]ピリミジン誘導体、その製造方法および医薬における使用 | |
US11731954B2 (en) | Histone demethylase inhibitors | |
CN112300153B (zh) | 一种杂环化合物、药物组合物和用途 | |
AU2013209586A1 (en) | Substituted pyrimidine compounds and their use as SYK inhibitors | |
CN118055933A (zh) | 选择性parp1抑制剂及其应用 | |
AU2012233246B2 (en) | Novel furanone derivative | |
CN110248658B (zh) | 吗啡喃衍生物的在阿片δ受体激动剂相关疾病的治疗中的应用 | |
WO2021129841A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
JP2009073743A (ja) | 新規な縮合環式ピリミジン化合物又はその塩、及びその医薬組成物 | |
KR102409595B1 (ko) | 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체 | |
CN115785074A (zh) | Parp7抑制剂及其用途 | |
WO2010126101A1 (ja) | プリン誘導体およびそれを用いた抗腫瘍剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980112760.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09730440 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010507175 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20107022154 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2720552 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009730440 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009234978 Country of ref document: AU Ref document number: 7111/DELNP/2010 Country of ref document: IN Ref document number: MX/A/2010/011097 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12937312 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010145526 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2009234978 Country of ref document: AU Date of ref document: 20090409 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0911679 Country of ref document: BR Kind code of ref document: A2 Effective date: 20101011 |